Tri-specific proteins and methods of use

Through the development of BCMA-binding three-specific proteins, the specific binding of it with CD3 and BCMA is used to achieve targeted treatment of tumor cells, and solve the problem that cancer treatment in the prior art is difficult to effectively destroy tumor cells without damaging healthy cells. Problem, showing efficient and non-toxic therapeutic effects.

CN118978600APending Publication Date: 2024-11-19HARPOON THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411066206.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-10-13
Filing Date
2018-10-12
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively and non-toxicly control the most lethal cancer, especially due to the lack of therapies that specifically destroy tumor cells without damaging healthy cells.

Method used

A BCMA-binding trispecific protein was developed, including a first domain that specifically binds to human CD3, a second domain that prolongs half-life and a third domain that specifically binds to BCMA, through the specificity of these domains Linker linkage, used to induce an immune response, and targeted therapy against tumor cells.

Benefits of technology

The protein can significantly prolong the body half-life, improve tissue penetration, enhance specific killing of tumor cells, and reduce damage to healthy cells, providing a potentially non-toxic and efficient cancer treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978600A_ABST
    Figure CN118978600A_ABST
Patent Text Reader

Abstract

Provided herein are B cell maturation agent (BCMA) targeted trispecific proteins comprising a domain that binds to CD3, a half-life extension domain, and a domain that binds to BCMA. The invention also provides a pharmaceutical composition thereof, and nucleic acid, a recombinant expression vector and a host cell for preparing the BCMA targeted trispecific protein. Also disclosed are methods of using the disclosed BCMA targeting tri-specific proteins to prevent and / or treat diseases, conditions, and disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese patent application with the application date of October 12, 2018, application number 201880080873.4, and invention name “Tri-specific proteins and methods of use” (the application date of the corresponding PCT application is October 12, 2018, and the application number is PCT / US2018 / 055659).

[0002] Cross-references

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 572,381, filed October 13, 2017, which is incorporated herein by reference in its entirety.

[0004] Sequence Listing

[0005] This application contains a sequence listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy created on October 11, 2018 is named 47517-723_601_SL.txt and is 752,020 bytes in size. Background Art

[0006] Cancer is the second leading cause of death in the human population after coronary heart disease. Millions of people die from cancer each year worldwide. In the United States alone, cancer kills well over 500,000 people each year, with approximately 1.4 million new cases diagnosed each year. Deaths from heart disease are declining significantly, while deaths from cancer have been rising. By the beginning of the next century, cancer is expected to become the leading cause of death.

[0007] And, even for those cancer patients who initially survive the primary cancer, the common experience is that their lives have been dramatically changed. Many cancer patients experience intense anxiety triggered by the realization of the possibility of recurrence or treatment failure. Many cancer patients experience significant physical weakness after treatment.

[0008] In general, a fundamental problem in controlling the most lethal cancers is the lack of effective and non-toxic systemic therapies. Cancer is a complex disease characterized by genetic mutations that lead to uncontrolled cell growth. Cancer cells are present in all organisms and under normal circumstances, their excessive growth is tightly regulated by various physiological factors. Summary of the invention

[0009] In a variety of clinical settings, it is often necessary to selectively destroy single cells or specific cell types. For example, the primary goal of cancer therapy is to specifically destroy tumor cells while leaving healthy cells and tissues intact and undamaged. One such approach is to induce an immune response against the tumor, so that immune effector cells such as natural killer (NK) cells or cytotoxic T lymphocytes (CTL) attack and destroy tumor cells.

[0010] Provided herein is a B cell maturation agent (BCMA) binding trispecific protein comprising: (a) a first domain (A) that specifically binds to human CD3; (b) a second domain (B) that is a half-life extension domain; and (c) a third domain (C) that specifically binds to BCMA, wherein the domains are linked in the order of H2N-(A)-(C)-(B)-COOH, H2N-(B)-(A)-(C)-COOH, H2N-(C)-(B)-(A)-COOH, H2N-(C)-(A)-(B)-COOH, H2N-(A)-(B)-(C)-COOH, or H2N-(B)-(C)-(A)-COOH, wherein the domains are linked by linkers L1 and L2.

[0011] In some cases, the first domain may comprise a variable light chain domain and a variable heavy chain domain, each capable of specifically binding to human CD3. The first domain may be humanized or human.

[0012] In some cases, the second domain binds albumin. The second domain may comprise a single chain variable fragment (scFv), a variable heavy chain domain (VH), a variable light chain domain (VL), a single chain antibody binding domain without a light chain (VHH domain), a peptide, a ligand, or a small molecule.

[0013] In some cases, the third domain is a single-chain antibody binding domain (VHH domain) that does not contain a light chain, scFv, VH domain, VL domain, non-Ig domain, ligand, knottin or small molecule entity that specifically binds to BCMA. In some non-limiting cases, the third domain comprises a VHH domain.

[0014] Provided herein is a BCMA-binding trispecific protein, wherein the VHH domain comprises complementarity determining regions CDR1, CDR2 and CDR3, wherein (a) the amino acid sequence of CDR1 is shown as X1X2X3X4X5X6X7PX8G (SEQ ID NO: 1), wherein X1 is T or S; X2 is N, D or S; X3 is I, D, Q, H, V or E; X4 is F, S, E, A, T, M, V, I, D, Q, P, R or G; X5 is S, M, R or N; X6 is I, K, S, T, R, E, D, N, V, H, L, A, Q or G; X7 is S, T, Y, R or N; and X8 is M, G or Y; (b) the amino acid sequence of CDR2 is shown as AIX9GX 10 X 11 TX 12 YADSVK (SEQ ID NO: 2) shows that X9 is H, N or S; X 10 is F, G, K, R, P, D, Q, H, E, N, T, S, A, I, L, or V; X 11 is S, Q, E, T, K or D; and X 12 is L, V, I, F, Y or W; and (c) the amino acid sequence of CDR3 is VPWGX 13 YXX 14 X 15 VX 16 (SEQ ID NO: 3) shows, wherein X 13 is D, I, T, K, R, A, E, S or Y; X 14 R, G, L, K, T, Q, S or N; X 15 is N, K, E, V, R, M or D; and X 16 Is Y, A, V, K, H, L, M, T, R, Q, C, S, or N.

[0015] In one embodiment, the CDR1 does not comprise the amino acid sequence of SEQ ID NO: 599. In one embodiment, the CDR2 does not comprise the amino acid sequence of SEQ ID NO: 600. In one embodiment, the CDR3 does not comprise the amino acid sequence of SEQ ID NO: 601. In one embodiment, the CDR1 and CDR2 do not comprise the amino acid sequences of SEQ ID NO: 599 and 600, respectively. In one embodiment, the CDR1 and CDR3 do not comprise the amino acid sequences of SEQ ID NO: 599 and 601, respectively. In one embodiment, the CDR2 and CDR3 do not comprise the amino acid sequences of SEQ ID NO: 600 and 601, respectively. In one embodiment, the CDR1, CDR2 and CDR3 do not comprise the amino acid sequences of SEQ ID NO: 599, 600 and 601, respectively.

[0016] Provided herein is a BCMA-binding trispecific protein, wherein the VHH domain comprises the formula: f1-r1-f2-r2-f3-r3-f4; wherein r1 is SEQ ID NO: 1; r2 is SEQ ID NO: 2; and r3 is SEQ ID NO: 3; and wherein f1, f2, f3, and f4 are selected framework residues such that the protein is about eighty percent (80%) to about 99% identical to the amino acid sequence set forth in SEQ ID NO: 598 or 346. Provided herein is a BCMA-binding trispecific protein, wherein the VHH domain comprises the formula: f1-r1-f2-r2-f3-r3-f4; wherein r1 is SEQ ID NO: 1; r2 is SEQ ID NO: 2; and r3 is SEQ ID NO: 3; and wherein f1, f2, f3, and f4 are selected framework residues such that the protein is about 80% to about 90% identical to the amino acid sequence set forth in SEQ ID NO: 598 or 346. In one embodiment, the amino acid sequence of the single domain BCMA-binding protein does not comprise SEQ ID NO:598.

[0017] In some non-limiting examples, r1 comprises an amino acid sequence as shown in any one of SEQ ID NOs: 4-117.

[0018] In some non-limiting examples, r2 comprises an amino acid sequence as shown in any one of SEQ ID NOs: 118-231.

[0019] In some non-limiting examples, r3 comprises an amino acid sequence as shown in any one of SEQ ID NOs: 232-345.

[0020] In other non-limiting examples, the protein comprises an amino acid sequence as shown in any one of SEQ ID NOs: 346-460.

[0021] In the single domain BCMA-binding protein, f1 in some cases comprises SEQ ID NO:461 or 462.

[0022] In the single domain BCMA binding protein, f2 in some cases comprises SEQ ID NO:463.

[0023] In the single domain BCMA binding protein, f3 in some cases comprises SEQ ID NO:464 or 465.

[0024] In a single domain BCMA-binding protein, wherein f4 in some cases comprises SEQ ID NO:466 or 467.

[0025] In a non-limiting example, r1 comprises SEQ ID NO:76, 114, 115, 116 or 117. In a non-limiting example, r1 comprises SEQ ID NO:76.

[0026] In one non-limiting example, r1 comprises SEQ ID NO:76, r2 is SEQ ID NO:190, and r3 is SEQ ID NO:304.

[0027] In one non-limiting example, r1 comprises SEQ ID NO:114, r2 comprises SEQ ID NO:228, and r3 comprises SEQ ID NO:342.

[0028] In one non-limiting example, r1 comprises SEQ ID NO:115, r2 comprises SEQ ID NO:229, and r3 comprises SEQ ID NO:343.

[0029] In a non-limiting example, r1 comprises SEQ ID NO:117, r2 comprises SEQ ID NO:231, and r3 comprises SEQ ID NO:345.

[0030] In one non-limiting example, r1 comprises SEQ ID NO:116, r2 comprises SEQ ID NO:230, and r3 comprises SEQ ID NO:344.

[0031] In some cases, the third domain is a human VHH domain, a humanized VHH domain, an affinity matured VHH domain, or a combination thereof.

[0032] In some instances, the BCMA-binding trispecific protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

[0033] The present invention provides a BCMA-binding trispecific protein, which is a VHH domain, wherein the VHH domain comprises CDR1, CDR2 and CDR3, and wherein the protein comprises the sequence of SEQ ID NO:346 or 598, wherein one or more amino acid residues selected from amino acid positions 26, 27, 28, 29, 30, 31, 32 and / or 34 of CDR1, positions 52, 54, 55 and / or 57 of CDR2, and positions 101, 105, 106 and / or 108 of CDR3 are replaced, wherein amino acid position 26, if replaced, is replaced by S; amino acid position 27, if replaced, is replaced by D or S; amino acid position 28, if replaced, is replaced by D, Q, H, V or E; amino acid position 29, if replaced, is replaced by S, E, A, T, M, V, I, D, Q, D, P, R or G; amino acid position 30, if replaced, is replaced by M, R or N; amino acid position 31, if replaced, is replaced by K, S, T, R, E, D, N, V, H, L, A, Q or G; amino acid position 3 amino acid position 2, if substituted, is substituted with T, Y, R or N; amino acid position 34, if substituted, is substituted with G or Y; amino acid position 52, if substituted, is substituted with N or S; amino acid position 54, if substituted, is substituted with G, K, R, P, D, Q, H, E, N, T, S, A, I, L or V; amino acid position 55, if substituted, is substituted with Q, E, T, K or D; amino acid position 57, if substituted, is substituted with V, I, F, Y or W; amino acid position 101, if substituted, is substituted with I, T, K, R, A, E, S or Y; amino acid position 105, if substituted, is substituted with G, L, K, T, Q, S or N; amino acid position 106, if substituted, is substituted with K, E, V, R, M or D; and amino acid position 108, if substituted, is substituted with A, V, K, H, L, M, T, R, Q, C, S or N. In a non-limiting example, the VHH domain is human, humanized, affinity matured, or a combination thereof.

[0034] Provided herein is a BCMA-binding trispecific protein, wherein the third domain binds to a human BCMA protein comprising a sequence as shown in SEQ ID NO: 468. In some cases, the third domain binds to an epitope of BCMA, wherein the epitope comprises the extracellular domain of BCMA. In some cases, the third domain binds to an epitope of BCMA, wherein the epitope comprises amino acid residues 5-51 of SEQ ID NO: 468.

[0035] In such BCMA-binding trispecific proteins, linkers L1 and L2 are each independently selected from (GS) n (SEQ ID NO:472), (GGS) n (SEQ ID NO:473), (GGGS) n (SEQ ID NO:474), (GGSG) n (SEQ ID NO:475), (GGSGG) n (SEQ ID NO:476), (GGGGS) n (SEQ ID NO:477), (GGGGG) n (SEQ ID NO:478) or (GGG) n (SEQ ID NO:479), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0036] In a non-limiting example, in such BCMA-binding trispecific proteins, linkers L1 and L2 are each independently (GGGGS)4 (SEQ ID NO: 480) or (GGGGS)3 (SEQ ID NO: 481).

[0037] The domains of the BCMA-binding trispecific protein may be linked in the order of H2N-(C)-(B)-(A)-COOH.

[0038] In some cases, the BCMA binding tri-specific protein is less than about 80 kDa. In other cases, the BCMA binding tri-specific protein can be about 50 to about 75 kDa. In other cases, the BCMA binding tri-specific protein is less than about 60 kDa.

[0039] In some cases, the elimination half-life of a BCMA-binding trispecific protein described herein is at least about 50 hours, about 100 hours, or longer.

[0040] In some cases, the BCMA-binding trispecific protein exhibits increased tissue penetration compared to IgG for the same BCMA.

[0041] In some cases, the BCMA-binding trispecific protein comprises an amino acid sequence selected from SEQ ID NOs: 483-597. In some cases, the BCMA-binding trispecific protein comprises an amino acid sequence as set forth in SEQ ID NO: 520.

[0042] In one embodiment, the present invention provides a B cell maturation agent (BCMA) binding trispecific protein, which comprises: (a) a first domain (A) that specifically binds to human CD3; (b) a second domain (B) that is a half-life extension domain; and (c) a third domain (C) that specifically binds to BCMA, wherein the third domain comprises the amino acid sequence shown in any one of SEQ ID NOs: 346-460.

[0043] In one embodiment, the present invention provides a B cell maturation agent (BCMA) binding trispecific protein, which comprises: (a) a first domain (A) that specifically binds to human CD3; (b) a second domain (B) that is a half-life extension domain; and (c) a third domain (C) that specifically binds to BCMA, wherein the third domain comprises CDR1, CDR2 and CDR3, wherein CDR1 comprises the amino acid sequence shown in any one of SEQ ID NOs: 4-117, CDR2 comprises the amino acid sequence shown in any one of SEQ ID NOs: 118-231, and CDR3 comprises the amino acid sequence shown in any one of SEQ ID NOs: 232-345.

[0044] Provided herein is a pharmaceutical composition comprising a BCMA-binding trispecific protein as described herein and a pharmaceutically acceptable carrier.

[0045] Also provided herein is a method for producing the BCMA-binding trispecific protein described herein, the method comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the BCMA-binding trispecific protein under conditions allowing expression of the BCMA-binding trispecific protein, and recovering and purifying the produced protein from the culture.

[0046] One embodiment provides a method for treating or ameliorating a BCMA-related neoplastic disease, autoimmune disease, or infectious disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a BCMA-binding trispecific protein, wherein the BCMA-binding protein comprises

[0047] (a) the first domain (A) that specifically binds to human CD3;

[0048] (b)(b) a second domain (B) which is a half-life extension domain; and

[0049] (c) (c) The third domain that specifically binds to BCMA (C),

[0050] (d) wherein the domains are connected in the order of H2N-(A)-(C)-(B)-COOH, H2N-(B)-(A)-(C)-COOH, H2N-(C)-(B)-(A)-COOH, H2N-(C)-(A)-(B)-COOH, H2N-(A)-(B)-(C)-COOH, H2N-(B)-(C)-(A)-COOH, and wherein the domains are connected via linkers L1 and L2.

[0051] Provided herein is a method for treating or improving a BCMA-related tumor disease, autoimmune disease, or infectious disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition as described herein.

[0052] In some cases, the subject to be treated is a human.

[0053] In some cases, the method further comprises administering one or more additional agents in conjunction with the BCMA-binding trispecific protein.

[0054] The methods described herein can be used to treat or ameliorate neoplastic diseases, wherein the BCMA-binding trispecific protein selectively binds to tumor cells expressing BCMA.

[0055] The neoplastic disease treated by the method includes a primary cancer or its metastasis. In one embodiment, the neoplastic disease includes a B-cell lineage cancer.

[0056] B-cell lineage cancers to be treated by the methods include, but are not limited to, multiple myeloma, leukemia, lymphoma, or metastases thereof.

[0057] Incorporation by reference

[0058] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] The novel features of the present invention are particularly set forth in the appended claims. The features and advantages of the present invention will be better understood by referring to the following detailed description of illustrative embodiments utilizing the principles of the present invention and the accompanying drawings, in which:

[0060] Figure 1 is a schematic diagram of an exemplary BCMA-targeting trispecific antigen-binding protein, wherein the protein has a constant core element comprising an anti-CD3ε single-chain variable fragment (scFv) and an anti-ALB variable heavy chain region; and an anti-BCMA binding domain, which can be a VHH, VH, scFv, non-Ig binder, or ligand.

[0061] Figure 2 Shown are the effects of exemplary BCMA targeting molecules (01H08, 01F07, 02F02, and BH253) containing anti-BCMA binding proteins according to the present disclosure in killing purified human T cells expressing BCMA compared to negative controls.

[0062] Figure 3 Representative SDS-PAGE images of purified BCMA trispecific molecules. Lane 1: 01F07-M34Y TriTAC, non-reducing; Lane 2: 01F07-M34G-TriTAC, non-reducing; Lane 3: 02B05 TriTAC, non-reducing; Lane 4: 02G02-M34Y TriTAC, non-reducing; Lane 5: 02G02 M34G TriTAC, non-reducing; Lane 6: Wide Range SDS-PAGE Standard (Bio-Rad #1610317); Lane 7: 01F07-M34Y TriTAC, non-reducing; Lane 8: 01F07-M34G-TriTAC, non-reducing; Lane 9: 02B05 TriTAC, non-reducing; Lane 10: 02G02-M34Y TriTAC, non-reducing; Lane 11: 02G02M34G TriTAC, non-reducing; Lane 12: Wide range SDS-PAGE standard (Bio-Rad #1610317).

[0063] Figures 4A-4I Shown is the effect of an exemplary BCMA trispecific targeting molecule containing an anti-BCMA binding protein according to the present disclosure in killing BCMA-expressing Jeko1, MOLP-8 or OPM-2 cells compared to a negative control.

[0064] Figures 5A-5D Binding of an exemplary BCMA trispecific targeting protein (02B05) to purified T cells from four different human donors is shown: Donor 02 ( Figure 5A )、Donor 35( Figure 5B )、Donor 81( Figure 5C )、Donor 86( Figure 5D ).

[0065] Figures 6A-6FAn exemplary BCMA trispecific targeting protein (02B05) is shown in Figure 2 and in the BCMA-expressing cell NCI-H929 ( Fig. 6A )、EJM( Figure 6B )、OPM2( Fig.6D )、RPMI8226( Fig. 6E ) or the cell line NCI-H510A lacking BCMA expression ( Figure 6C ) and DMS-153( Fig. 6F ) combination.

[0066] Figure 7 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05) and BCMA-expressing EJM cells in the presence or absence of human serum albumin (HSA).

[0067] Figure 8 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05) and BCMA-expressing EJM cells using different effector cell to target cell ratios.

[0068] Fig. 9 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05) and BCMA-expressing OPM2 cells using different effector cell to target cell ratios.

[0069] Fig.10 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05) and BCMA-expressing NCI-H929 cells using different time points and a 1:1 effector to target cell ratio.

[0070] Fig.11 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05), BCMA-expressing EJM cells, and T cells from four different donors in the presence of human serum albumin (HSA).

[0071] Fig.12 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05), BCMA-expressing NCI-H929 cells, and T cells from four different donors in the presence of human serum albumin (HSA).

[0072] Fig.13Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05), BCMA-expressing OPM2 cells, and T cells from four different donors in the presence of human serum albumin (HSA).

[0073] Fig.14 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05), BCMA-expressing RPMI8226 cells, and T cells from four different donors in the presence of human serum albumin (HSA).

[0074] Fig.15 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05), OVCAR8 cells that do not express BCMA, and T cells from four different donors in the presence of human serum albumin (HSA).

[0075] Fig.16 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05), NCI-H510A cells that do not express BCMA, and T cells from four different donors in the presence of human serum albumin (HSA).

[0076] Fig.17 Shown are the results of a TDCC assay performed using an exemplary BCMA trispecific targeting protein (02B05), BCMA-expressing NCI-H929 cells, and peripheral blood mononuclear cells (PBMCs) from two different cynomolgus monkey donors in the presence of human serum albumin (HSA).

[0077] Fig.18 Shown are the results of a TDCC assay using an exemplary BCMA trispecific targeting protein (02B05), BCMA-expressing RPMI8226 cells, and peripheral blood mononuclear cells (PBMCs) from two different cynomolgus monkey donors in the presence of human serum albumin (HSA).

[0078] Fig.19 Shown are the expression levels of the T cell activation biomarker CD69 following TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and BCMA-expressing cells EJM.

[0079] Fig. 20 Shown are the expression levels of the T cell activation biomarker CD25 following TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and BCMA-expressing cells EJM.

[0080] Fig.21 Shown are the expression levels of the T cell activation biomarker CD69 following a TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and BCMA-expressing cells OPM2.

[0081] Fig. 22 Shown are the expression levels of the T cell activation biomarker CD25 following a TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and BCMA-expressing cells OPM2.

[0082] Fig.23 Shown are the expression levels of the T cell activation biomarker CD69 following a TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and BCMA-expressing cells RPMI8226.

[0083] Fig.24 Shown are the expression levels of the T cell activation biomarker CD25 following a TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and BCMA-expressing cells RPMI8226.

[0084] Fig.25 Shown are the expression levels of the T cell activation biomarker CD69 following TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and cells OVCAR8 that do not express BCMA.

[0085] Fig.26 Shown are the expression levels of the T cell activation biomarker CD25 following TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and cells OVCAR8 that do not express BCMA.

[0086] Fig. 27 Shown are the expression levels of the T cell activation biomarker CD69 following TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and cells NCI-H510A that do not express BCMA.

[0087] Fig.28 Shown are the expression levels of the T cell activation biomarker CD25 following TDCC assay using an exemplary BCMA-targeting trispecific protein (02B05) and cells NCI-H510A that do not express BCMA.

[0088] Fig.29Shown are the expression levels of the cytokine TNF-α in co-cultures of T cells and BCMA-expressing target cells (EJM cells) treated with increasing concentrations of an exemplary BCMA-targeting trispecific (02B05) protein or with a negative control GFP trispecific protein.

[0089] Fig.30 Shown is the reduction in tumor growth in the RPMI8226 xenograft model treated with various concentrations of an exemplary BCMA-targeting trispecific (02B05) protein or with a control vehicle.

[0090] Fig.31 Shown is the reduction of tumor growth in the Jeko1 xenograft model treated with various concentrations of an exemplary BCMA-targeting trispecific (02B05) protein or with a control vehicle.

[0091] Fig.32 Shown are the concentrations of BCMA-targeting trispecific proteins in serum samples from cynomolgus monkeys administered different concentrations of an exemplary BCMA-targeting trispecific (02B05) protein.

[0092] Fig.33 are the results of a TDCC assay using BCMA trispecific targeting proteins, BCMA-expressing EJM cells, and purified human T cells obtained from serum samples of cynomolgus monkeys collected 168 hours after administration of different concentrations of an exemplary BCMA-targeting trispecific (02B05) protein in the presence of serum from cynomolgus monkeys not exposed to the BCMA-targeting trispecific protein. DETAILED DESCRIPTION

[0093] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Those skilled in the art will now appreciate many variations, changes, and substitutions without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be employed in the process of implementing the present invention. It is intended that the scope of the present invention be defined by the following claims, and that methods and structures and their equivalents within the scope of these claims are thereby encompassed.

[0094] Described herein are trispecific proteins targeting B cell maturation antigen (BCMA), pharmaceutical compositions thereof (referred to herein as BCMA binding trispecific proteins, BCMA targeting trispecific proteins, or BCMA trispecific antigen binding proteins), and nucleic acids, recombinant expression vectors, and host cells for preparing such proteins thereof. Also provided are methods for preventing and / or treating diseases, conditions, and disorders using the disclosed BCMA targeting trispecific proteins. The BCMA targeting trispecific protein is capable of specifically binding to BCMA and CD3, and has a half-life extension domain such as a domain that binds to human albumin (ALB). Figure 1 Non-limiting examples of trispecific BCMA-binding proteins are depicted.

[0095] "Antibody" generally refers to a Y-shaped tetrameric protein comprising two heavy (H) polypeptide chains and two light (L) polypeptide chains held together by covalent disulfide bonds and non-covalent interactions. Human light chains comprise a variable domain (VL) and a constant domain (CL), wherein the constant domain can be readily classified as either κ or λ based on amino acid sequence and locus. Each heavy chain comprises a variable domain (VH) and a constant region, which in the case of IgG, IgA and IgD comprises three domains, referred to as CH1, CH2 and CH3, respectively (IgM and IgE have a fourth domain, CH4). In the IgG, IgA and IgD classes, the CH1 and CH2 domains are separated by a flexible hinge region, which is a proline and cysteine-rich segment of variable length (usually about 10 to about 60 amino acids in IgG). The variable domains in both the light and heavy chains are connected to the constant domains by a "J" region of about 12 or more amino acids, and the heavy chain also has a "D" region of about 10 additional amino acids. Each class of antibodies further comprises interchain and intrachain disulfide bonds formed by paired cysteine ​​residues. There are two types of natural disulfide bridges or disulfide bonds in immunoglobulin molecules: interchain and intrachain disulfide bonds. The position and number of interchain disulfide bonds vary depending on the class and type of immunoglobulin. Interchain disulfide bonds are located on the surface of immunoglobulins, are solvent accessible, and are generally relatively easy to reduce. In the human IgG1 isotype, there are four interchain disulfide bonds, one from each heavy chain to the light chain, and two between the heavy chains. Interchain disulfide bonds are not required for chain association. It is well known that the cysteine-rich IgG1 hinge region of the heavy chain is usually maintained as consisting of three parts: an upper hinge, a core hinge, and a lower hinge. Those skilled in the art will appreciate that the IgG1 hinge region contains cysteines in the heavy chain that form interchain disulfide bonds (two heavy / heavy, two heavy / light) that provide structural flexibility that facilitates Fab movement. The interchain disulfide bond between the light and heavy chains of IgG1 is formed between C214 of the kappa or lambda light chain and C220 in the hinge region on the heavy chain. The interchain disulfide bond between the heavy chains is located at positions C226 and C229 (all numbered according to the EU index, according to Kabat et al., below).

[0096] As used herein, the term "antibody" includes polyclonal antibodies, polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized and primatized antibodies, CDR-grafted antibodies, human antibodies, recombinantly produced antibodies, intrabodies, multispecific antibodies, bispecific antibodies, monovalent antibodies, multivalent antibodies, anti-idiotypic antibodies, synthetic antibodies, including muteins and variants thereof, immunospecific antibody fragments, such as Fd, Fab, F(ab')2, F(ab') fragments, single-chain fragments (e.g., ScFv and ScFvFc), disulfide-linked Fv (sdFv), Fd fragments consisting of VH and CH1 domains, linear antibodies, single domain antibodies, such as sdAb (VH, VL or VHH domains); and derivatives thereof, including Fc fusions and other modifications, as well as any other immunoreactive molecules, as long as they contain a domain having a binding site that preferentially associates or binds to a BCMA protein. In addition, unless otherwise indicated by contextual constraints, the term also includes antibodies of all classes (i.e., IgA, IgD, IgE, IgG, and IgM) and all subclasses (i.e., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). The heavy chain constant domains corresponding to the different antibody classes are generally represented by the corresponding lowercase Greek letters α, δ, ε, γ, and μ, respectively. The light chains of antibodies from any vertebrate species can be classified into one of two distinct types (called κ (kappa) and λ (lambda)) based on the amino acid sequence of their constant domains.

[0097] In some embodiments, the BCMA binding domain of the BCMA targeting trispecific protein of the present disclosure comprises only a heavy chain antibody, such as a VH or VHH domain. In some cases, the BCMA binding protein comprises only a heavy chain antibody, which is an engineered VH domain. In some instances, the engineered human VH domain is produced by panning a phage display library. In some embodiments, the BCMA binding domain of the BCMA targeting trispecific protein of the present disclosure comprises a VHH. The term "VHH" as used herein refers to a single-chain antibody binding domain that does not contain a light chain. In some cases, VHH is derived from an antibody of a type that naturally lacks a light chain that can be found in camelids or cartilaginous fish, or from a synthetic and non-immune VHH that can be constructed accordingly. Each heavy chain comprises a variable region encoded by V-, D- and J- exons. In some cases, VHH is a natural VHH, such as a VHH from a camelid family, or a recombinant protein comprising a heavy chain variable domain. In some embodiments, the VHH is derived from a species selected from camels, llamas, vicugnas, guanacos, and cartilaginous fish (such as, but not limited to, sharks). In another embodiment, the VHH is derived from an alpaca (such as, but not limited to, a Huacaya Alpaca or a Surialpaca).

[0098] As used herein, "variable region" or "variable domain" refers to the following situation: some parts of the variable domain are widely different in sequence between antibodies, and are used in the binding and specificity of each specific antibody to its specific antigen. However, the variability is not evenly distributed throughout the variable domain of the antibody. It is concentrated in three segments called complementary determining regions (CDRs) or hypervariable regions in the light chain (VL) and heavy chain (VH) variable domains. The more highly conserved parts of the variable domain are called frameworks (FRs). The variable domains of natural heavy and light chains each contain four FR regions, which mainly adopt a β-folded configuration, connected by three CDRs, which form loops connecting the β-folded structure, and in some cases form a part of the β-folded structure. The CDRs in each chain are kept together in close proximity by the FR region, and together with the CDRs from the other chain, help to form the antigen binding site of the antibody (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). Although the constant domain is not directly involved in the binding of the antibody to the antigen, it exhibits various effector functions, such as the antibody's participation in the antibody-dependent cellular toxicity of the antibody. In some cases, the scFv fragment (or single-chain fragment variable) obtained by genetic engineering associates the VH and VL regions of the antibody in a single polypeptide chain, and the two regions are separated by a peptide linker.

[0099] In some embodiments of the present disclosure, the BCMA-binding domain of the BCMA-targeting trispecific protein comprises a heavy chain-only antibody, such as a VH or VHH domain, and comprises three CDRs. In some embodiments, such heavy chain-only antibodies bind to BCMA in a monomeric form, and their optimal binding affinity is independent of dimerization with the VL (light chain variable) region. In some embodiments of the present disclosure, the CD3 binding domain of the BCMA-targeting trispecific protein comprises an scFv. In some embodiments of the present disclosure, the albumin binding domain of the BCMA-targeting trispecific protein comprises a heavy chain-only antibody, such as a single domain antibody comprising a VH domain or a VHH domain.

[0100] In some embodiments, unless otherwise indicated, the assignment of amino acids to each domain, framework region, and CDR is according to one of the numbering schemes provided by Kabat et al. (1991) Sequences of Proteins of Immunological Interest (5th Edition), USDept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242; Chothia et al., 1987, PMID: 3681981; Chothia et al., 1989, PMID: 2687698; MacCallum et al., 1996, PMID: 8876650; or Dubel, Ed. (2007) Handbook of Therapeutic Antibodies, 3rd Edition, Wily-VCH Verlag GmbH and Co or AbM (Oxford Molecular / MSI Pharmacopia). This does not mean that the CDRs disclosed herein necessarily correspond to the Kabat numbering convention.

[0101] The term "framework" or "FR" residues (or regions) refers to variable domain residues other than CDR or hypervariable region residues as defined herein. A "human consensus framework" is a framework representing the most commonly occurring amino acid residues in selected human immunoglobulin VL or VH framework sequences.

[0102] As used herein, the term " amino acid sequence identity percentage (%) " for sequence is defined as the percentage that the amino acid residue in the candidate sequence is identical with the amino acid residue in the specific sequence after the sequence is compared and introduced into room (if necessary) to reach maximum sequence identity percentage, and any conservative substitution is not considered to be a part for sequence identity. The comparison for determining the amino acid sequence identity percentage purpose can be realized by the various ways within the technical scope of the art, for example, using publicly available computer software, such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring the comparison, including any algorithm required for maximum comparison on the total length of the compared sequence.

[0103] As used herein, "elimination half-life" is used in its ordinary sense, as described in Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 21-25 (Alfred Goodman Gilman, Louis S. Goodman and Alfred Gilman, eds., 6th edition 1980). In short, the term is intended to include a quantitative measure of the time course of drug elimination. The elimination of most drugs is exponential (i.e., follows first-order kinetics) because the drug concentration is usually not close to the concentration required for saturation of the elimination process. The rate of an exponential process can be represented by its rate constant k or by its half-life t1 / 2, where the rate constant k represents the fractional change per unit time, and the half-life t1 / 2 represents the time required for the process to complete 50%. The units of these two constants are time-1 and time, respectively. The first-order rate constant and half-life of the reaction are simply related (k×t1 / 2=0.693) and can be interchanged accordingly. Since first-order elimination kinetics indicate that a constant fraction of drug is lost per unit time, a plot of the logarithm of drug concentration versus time is linear after the initial distribution phase (i.e., after drug absorption and distribution are complete). The half-life of drug elimination can be accurately determined from such a plot.

[0104] As used herein, the term "binding affinity" refers to the affinity of a protein described in the present disclosure for its binding target, and is expressed numerically using a "Kd" value. If two or more proteins are shown to have comparable binding affinities for their binding targets, then the Kd values ​​for binding of each protein to its binding target are within ±2 times of each other. If two or more proteins are shown to have comparable binding affinities for a single binding target, then the Kd values ​​for binding of each protein to the single binding target are within ±2 times of each other. If a protein is shown to bind two or more targets with comparable binding affinities, then the Kd values ​​for binding of the protein to the two or more targets are within ±2 times of each other. Generally, higher Kd values ​​correspond to weaker binding. In some embodiments, using BIAcore TM -2000 or BIAcore TM "Kd" is measured by radiolabeled antigen binding assay (RIA) or surface plasmon resonance assay using a BIAcore-3000 (BIAcore, Inc., Piscataway, NJ). In certain embodiments, BIAcore TM -2000 or BIAcore TM The "association rate" or "association rate" or "association rate" or "kon" and the "dissociation rate" or "dissociation rate" or "dissociation rate" or "koff" are measured by surface plasmon resonance technology using a BIAcore-3000 (BIAcore, Inc., Piscataway, NJ). In another embodiment, the Systems (Pall Life Sciences) to determine "Kd", "kon", and "koff". In an exemplary method for measuring binding affinity using a PCR system, a ligand (e.g., biotinylated human or cynomolgus monkey BCMA) is immobilized on On the surface of the streptavidin capillary sensor tip, the streptavidin tip is then activated using about 20-50 μg / ml of human or cynomolgus monkey BCMA protein according to the manufacturer's instructions. A PBS / casein solution is also introduced as a blocking agent. For association kinetics measurements, BCMA binding protein variants are introduced at a concentration of about 10 ng / mL to about 100 μg / mL, about 50 ng / mL to about 5 μg / mL, or about 2 ng / mL to about 20 μg / mL. In some embodiments, BCMA binding single domain proteins are used at a concentration of about 2 ng / mL to about 20 μg / mL. Complete dissociation was observed in the negative control, i.e., in the case of an assay buffer without binding protein. Appropriate tools such as ForteBio software are then used to determine the kinetic parameters of the binding reaction.

[0105] The term "about" or "approximately" means within an acceptable error range for a particular value determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., limitations of the measurement system. For example, depending on the practice of a given value, "about" can mean within 1 or more than 1 standard deviation. Where specific values ​​are described in the application and claims, the term "about" should be considered to mean an acceptable error range for that specific value unless otherwise stated.

[0106] The terms "individual," "patient," or "subject" are used interchangeably. None of these terms require or are limited to situations characterized by monitoring (e.g., continuous or intermittent) by a health care worker (e.g., a physician, registered nurse, nurse practitioner, physician assistant, caregiver, or hospice worker).

[0107] The terms used herein are for the purpose of describing a particular situation only and are not intended to be limiting. Unless the context clearly dictates otherwise, the singular forms "a", "an", and "the" as used herein are intended to include the plural forms as well. In addition, to the extent that the terms "includes", "comprising", "having", or variations thereof are used in the detailed description and / or claims, these terms are intended to be inclusive in a manner similar to the term "comprising".

[0108] In one aspect, the BCMA-targeted trispecific protein comprises a domain (A) that specifically binds to CD3, a domain (B) that specifically binds to human albumin (ALB), and a domain (C) that specifically binds to BCMA. The three domains in the BCMA-targeted trispecific protein are arranged in any order. Therefore, considering that the domain order of the BCMA-targeted trispecific protein is:

[0109] H2N-(A)-(B)-(C)-COOH,

[0110] H2N-(A)-(C)-(B)-COOH,

[0111] H2N-(B)-(A)-(C)-COOH,

[0112] H2N-(B)-(C)-(A)-COOH,

[0113] H2N-(C)-(B)-(A)-COOH, or

[0114] H2N-(C)-(A)-(B)-COOH.

[0115] In some embodiments, the BCMA-targeting tri-specific protein has a domain order of H2N-(A)-(B)-(C)-COOH. In some embodiments, the BCMA-targeting tri-specific protein has a domain order of H2N-(A)-(C)-(B)-COOH. In some embodiments, the BCMA-targeting tri-specific protein has a domain order of H2N-(B)-(A)-(C)-COOH. In some embodiments, the BCMA-targeting tri-specific protein has a domain order of H2N-(B)-(C)-(A)-COOH. In some embodiments, the BCMA-targeting tri-specific protein has a domain order of H2N-(C)-(B)-(A)-COOH. In some embodiments, the BCMA-targeting tri-specific protein has a domain order of H2N-(C)-(A)-(B)-COOH. In some embodiments, the BCMA-targeting tri-specific protein has a domain order of H2N-(C)-(A)-(B)-COOH. In some embodiments, the anti-BCMA domain (anti-target domain, T), anti-CD3 domain (C) and anti-ALB domain (A) are in the direction of anti-CD3: anti-ALB: anti-BCMA (CAT). In some embodiments, the anti-BCMA domain (anti-target domain, T), anti-CD3 domain (C) and anti-ALB domain (A) are in the direction of anti-BCMA: anti-ALB: anti-CD3 (TAC).

[0116] In some embodiments, the BCMA targeting trispecific protein has an HSA binding domain as the middle domain, such that the domain order is H2N-(A)-(B)-(C)-COOH or H2N-(C)-(B)-(A)-COOH. It is expected that in such embodiments where the ALB binding domain is the middle domain, the CD3 and BCMA binding domains are endowed with additional flexibility to bind to their respective targets.

[0117] In some embodiments, the BCMA targeting trispecific protein described herein comprises a polypeptide having a sequence described in the sequence list (SEQ ID NO: 483-597) and a subsequence thereof. In some embodiments, the trispecific antigen binding protein comprises a polypeptide having at least 70%-95% or more homology with the sequence described in the sequence list (SEQ ID NO: 483-597). In some embodiments, the trispecific antigen binding protein comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95% or more homology with the sequence described in Sequence Listing 1 (SEQ ID NO: 483-597).

[0118] The BCMA targeting tri-specific proteins described herein are designed to allow specific targeting of cells expressing BCMA by recruiting cytotoxic T cells. This improves efficacy compared to ADCC (antibody-dependent cell-mediated cytotoxicity), which uses full-length antibodies against a unique antigen and cannot directly recruit cytotoxic T cells. On the contrary, by engaging CD3 molecules specifically expressed on these cells, the BCMA targeting tri-specific proteins can cross-link cytotoxic T cells with cells expressing BCMA in a highly specific manner, thereby directing the cytotoxic potential of T cells to target cells. The BCMA targeting tri-specific proteins described herein engage cytotoxic T cells via binding to surface-expressed CD3 proteins, which form part of TCR. Several BCMA tri-specific antigen binding proteins simultaneously bind to CD3 and BCMA expressed on the surface of specific cells to cause T cell activation, and mediate subsequent lysis of specific BCMA-expressing cells. Therefore, it is expected that BCMA targeting tri-specific proteins show strong, specific and effective target cell killing. In some embodiments, the BCMA targeting tri-specific proteins described herein stimulate cytotoxic T cells to kill target cells to eliminate pathogenic cells (e.g., tumor cells expressing BCMA). In some such embodiments, cells are selectively eliminated, thereby reducing the likelihood of toxic side effects.

[0119] Compared with traditional monoclonal antibodies and other smaller bispecific molecules, the BCMA-targeted trispecific proteins described herein provide further therapeutic advantages. In general, the effectiveness of recombinant protein drugs depends largely on the intrinsic pharmacokinetics of the protein itself. One such advantage is that the BCMA-targeted trispecific proteins described herein have an extended pharmacokinetic elimination half-life due to having a half-life extension domain, such as an HSA-specific domain. In this regard, in some embodiments, the BCMA-targeted trispecific proteins described herein have an extended serum elimination half-life of about two days, three days, about five days, about seven days, about 10 days, about 12 days, or about 14 days. This is in contrast to other binding proteins such as BiTE or DART molecules with a relatively much shorter elimination half-life. For example, BiTE CD19×CD3 bispecific scFv-scFv fusion molecules require continuous intravenous infusion (iv) drug delivery due to their short elimination half-life. The longer intrinsic half-life of the BCMA-targeting trispecific protein addresses this problem, allowing for increased therapeutic potential such as lower-dose drug formulations, reduced regular dosing, and / or novel pharmaceutical compositions.

[0120] The BCMA targeting tri-specific proteins described herein also have an optimal size for enhanced tissue penetration and tissue distribution. Larger sizes limit or prevent the penetration or distribution of proteins in target tissues. The BCMA targeting tri-specific proteins described herein avoid this problem by having a small size that allows enhanced tissue penetration and distribution. Therefore, in some embodiments, the size of the BCMA targeting tri-specific proteins described herein is about 50kD to about 80kD, about 50kD to about 75kD, about 50kD to about 70kD, or about 50kD to about 65kD. Therefore, the size of the BCMA targeting tri-specific protein is superior to the IgG antibody of about 150kD and the BiTE and DART double antibody molecules of about 55kD but the half-life is not extended and is therefore quickly cleared by the kidneys.

[0121] In further embodiments, the BCMA-targeting tri-specific proteins described herein have an optimal size for enhanced tissue penetration and distribution. In these embodiments, the BCMA-targeting tri-specific proteins are constructed to be as small as possible while retaining specificity for their targets. Thus, in these embodiments, the size of the BCMA-targeting tri-specific proteins described herein is about 20 kD to about 40 kD, or about 25 kD to about 35 kD to about 40 kD, to about 45 kD, to about 50 kD, to about 55 kD, to about 60 kD, to about 65 kD. In some embodiments, the size of the BCMA targeting trispecific proteins described herein is about 50 kD, 49 kD, 48 kD, 47 kD, 46 kD, 45 kD, 44 kD, 43 kD, 42 kD, 41 kD, 40 kD, about 39 kD, about 38 kD, about 37 kD, about 36 kD, about 35 kD, about 34 kD, about 33 kD, about 32 kD, about 31 kD, about 30 kD, about 29 kD, about 28 kD, about 27 kD, about 26 kD, about 25 kD, about 24 kD, about 23 kD, about 22 kD, about 21 kD, or about 20 kD. An exemplary method to achieve a small size is to use a single domain antibody (sdAb) fragment for each domain. For example, a specific BCMA trispecific antigen binding protein has an anti-CD3 sdAb, an anti-ALB sdAb, and an sdAb for BCMA. This reduces the size of the exemplary BCMA trispecific antigen binding protein to less than 40kD. Therefore, in some embodiments, the domains of the BCMA targeting trispecific protein are all single domain antibody (sdAb) fragments. In other embodiments, the BCMA targeting trispecific protein described herein comprises a small molecule entity (SME) conjugate for ALB and / or BCMA. The SME conjugate is a small molecule with an average size of about 500Da to 2000Da, and is attached to the BCMA targeting trispecific protein by known methods such as sortase connection or conjugation. In these examples, one of the domains of the BCMA trispecific antigen binding protein is a sortase recognition sequence, for example, LPETG (SEQ ID NO: 482). In order to attach the SME conjugate to the BCMA trispecific antigen binding protein with a sortase recognition sequence, the protein is incubated with a sortase and a SME conjugate, so that the sortase attaches the SME conjugate to the recognition sequence. Known SME binders include MIP-1072 and MIP-1095, which bind to BCMA.

[0122] In yet other embodiments, the domain that binds to BCMA in the BCMA-targeted trispecific protein described herein comprises a knottin peptide for binding to BCMA. Knottin is a disulfide-stabilized peptide with a cysteine ​​knot scaffold and has an average size of about 3.5 kD. Knottin is expected to bind to certain tumor molecules such as BCMA. In a further embodiment, the domain that binds to BCMA in the BCMA-targeted trispecific protein described herein comprises a natural BCMA ligand.

[0123] Another feature of the BCMA-targeted trispecific proteins described herein is that they are designed as single polypeptides with flexible connections of their domains. This allows for easy generation and preparation of BCMA-targeted trispecific proteins because they can be encoded by a single cDNA molecule that is easily introduced into a vector. In addition, since the BCMA-targeted trispecific proteins described herein are monomeric single polypeptide chains, there are no chain pairing problems or dimerization required. It is expected that the BCMA-targeted trispecific proteins described herein have a reduced tendency to aggregate, unlike other reported molecules, such as bispecific proteins with Fc-γ immunoglobulin domains.

[0124] In the BCMA targeting trispecific protein described herein, the domains are connected by internal connectors L1 and L2, wherein L1 connects the first and second domains of the BCMA targeting trispecific protein, and L2 connects the second and third domains of the BCMA targeting trispecific protein. Connectors L1 and L2 have optimized lengths and / or amino acid compositions. In some embodiments, connectors L1 and L2 have the same length and amino acid composition. In other embodiments, L1 and L2 are different. In certain embodiments, internal connectors L1 and / or L2 are "short", that is, composed of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Therefore, in certain instances, the internal connector is composed of about 12 or fewer amino acid residues. In the case of 0 amino acid residues, the internal connector is a peptide bond. In certain embodiments, internal connectors L1 and / or L2 are "long", that is, composed of 15, 20 or 25 amino acid residues. In some embodiments, the internal linkers consist of about 3 to about 15, such as 8, 9 or 10 consecutive amino acid residues. Regarding the amino acid composition of the internal linkers L1 and L2, peptides are selected that have the following properties, namely, they can confer flexibility to the BCMA targeting trispecific protein, do not interfere with the binding domain, and resist protease cleavage. For example, glycine and serine residues generally provide protease resistance. Examples of internal linkers suitable for linking domains in a BCMA targeting trispecific protein include, but are not limited to, (GS)n(SEQ ID NO:472), (GGS)n(SEQ ID NO:473), (GGGS)n(SEQ ID NO:474), (GGSG)n(SEQ ID NO:475), (GGSGG)n(SEQ ID NO:476), (GGGGS)n(SEQ ID NO:477), (GGGGG)n(SEQ ID NO:478), or (GGG)n(SEQ ID NO:479), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the internal linker L1 and / or L2 is (GGGGS)4(SEQ ID NO:480) or (GGGGS)3(SEQ ID NO:481).

[0125] CD3 binding domain

[0126] The specificity of the T cell response is mediated by the recognition of antigens (displayed in the context of the major histocompatibility complex MHC) by the TCR. As part of the TCR, CD3 is a protein complex that contains the CD3γ(gamma) chain, the CD3δ(delta) chain, and two CD3ε(epsilon) chains present on the cell surface. CD3 associates with the α(alpha) and β(beta) chains of the TCR and together with CD3ζ(zeta) constitutes the complete TCR. Clustering of CD3 on T cells, such as by immobilized anti-CD3 antibodies, results in T cell activation, which is similar to the engagement of the T cell receptor, but is independent of its clone-specific specificity.

[0127] In one aspect, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to CD3. In one aspect, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to human CD3. In some embodiments, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to CD3γ. In some embodiments, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to CD3δ. In some embodiments, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to CD3ε.

[0128] In further embodiments, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to a TCR. In certain instances, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to the α chain of a TCR. In certain instances, the BCMA-targeted trispecific proteins described herein comprise a domain that specifically binds to the β chain of a TCR.

[0129] In some embodiments, the CD3 binding domain of the BCMA trispecific antigen-binding protein can be any domain that binds to CD3, including but not limited to domains from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, and humanized antibodies. In some cases, it is beneficial that the CD3 binding domain is derived from the same species in which the BCMA trispecific antigen-binding protein will ultimately be used. For example, for human use, it may be beneficial for the CD3 binding domain of the BCMA trispecific antigen-binding protein to contain human or humanized residues from the antigen-binding domain of an antibody or antibody fragment.

[0130] Thus, in one aspect, the antigen binding domain comprises a humanized or human antibody or antibody fragment, or a murine antibody or antibody fragment. In one embodiment, the humanized or human anti-CD3 binding domain comprises one or more (e.g., all three) of the light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of the humanized or human anti-CD3 binding domain described herein, and / or one or more (e.g., all three) of the heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of the humanized or human anti-CD3 binding domain described herein, e.g., the humanized or human anti-CD3 binding domain comprises one or more, e.g., all three LC CDRs, and one or more, e.g., all three HC CDRs.

[0131] In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human light chain variable region specific for CD3, wherein the light chain variable region specific for CD3 comprises a human or non-human light chain CDR in a human light chain framework region. In certain instances, the light chain framework region is a lambda light chain framework. In other instances, the light chain framework region is a kappa light chain framework.

[0132] In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human heavy chain variable region that is specific for CD3, wherein the heavy chain variable region that is specific for CD3 comprises human or non-human heavy chain CDRs in the human heavy chain framework region.

[0133] In certain examples, the complementarity determining regions of the heavy and / or light chains are derived from known anti-CD3 antibodies, e.g., muromonab CD3 (OKT3), otelizumab (TRX4), telizumab (MGA031), visilizumab (Nuvion), SP34, TR-66 or X35-3, VIT3, BMA030 (BW264 / 56), CLB-T3 / 3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR-66, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3 / RW2-8C8, T3 / RW2-4B6, OKT3D, M-T301, SMC2, F101.01, UCHT-1, and WT-31.

[0134] In one embodiment, the anti-CD3 binding domain is a single chain variable fragment (scFv) of a light chain and a heavy chain comprising an amino acid sequence provided herein. As used herein, a "single chain variable fragment" or "scFv" refers to an antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light chain and heavy chain variable regions are continuously connected via a short flexible polypeptide connector and can be expressed as a single polypeptide chain, and wherein the scFv retains the specificity of the intact antibody from which it is derived. In one embodiment, the anti-CD3 binding domain comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of an amino acid sequence of a light chain variable region provided herein, or a sequence having 95%-99% identity with an amino acid sequence provided herein; and / or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of an amino acid sequence of an amino acid sequence of a heavy chain variable region provided herein, or a sequence having 95%-99% identity with an amino acid sequence provided herein. In one embodiment, the humanized or human anti-CD3 binding domain is a scFv, and the light chain variable region comprising the amino acid sequence described herein is attached to the heavy chain variable region comprising the amino acid sequence described herein via an scFv connector. The light chain variable region and heavy chain variable region of the scFv can be, for example, in any of the following orientations: light chain variable region-scFv linker-heavy chain variable region or heavy chain variable region-scFv linker-light chain variable region.

[0135] In some examples, scFvs that bind to CD3 are prepared according to known methods. For example, scFv molecules can be produced by connecting VH and VL regions together using a flexible polypeptide connector. The scFv molecule comprises an scFv connector (e.g., a Ser-Gly connector) having an optimized length and / or amino acid composition. Therefore, in some embodiments, the length of the scFv connector allows the VH or VL domain to be intermolecularly associated with other variable domains to form a CD3 binding site. In certain embodiments, such scFv connectors are "short", i.e., composed of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Therefore, in certain examples, the scFv connector is composed of about 12 or fewer amino acid residues. In the case of 0 amino acid residues, the scFv connector is a peptide bond. In some embodiments, these scFv connectors are composed of about 3 to about 15, for example 8, 9 or 10 continuous amino acid residues. Regarding the amino acid composition of the scFv linker, peptides are selected that confer flexibility, do not interfere with the variable domains, and allow interchain folding so that the two variable domains together form a functional CD3 binding site. For example, scFv linkers comprising glycine and serine residues generally provide protease resistance. In some embodiments, the linker in the scFv comprises glycine and serine residues. The amino acid sequence of the scFv linker can be optimized by, for example, phage display to improve the CD3 binding and yield of the scFv. Examples of peptide scFv linkers suitable for connecting the variable light chain domain and the variable heavy chain domain in the scFv include, but are not limited to (GS)n (SEQ ID NO: 472), (GGS) n (SEQ ID NO:473), (GGGS) n (SEQ ID NO:474), (GGSG) n (SEQ ID NO:475), (GGSGG) n (SEQ ID NO:476), (GGGGS) n (SEQ ID NO:477), (GGGGG) n (SEQ ID NO:478) or (GGG) n (SEQ ID NO: 479), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In one embodiment, the internal linker L1 and / or L2 is (GGGGS)4 (SEQ ID NO: 480) or (GGGGS)3 (SEQ ID NO: 481). Variations in linker length can maintain or enhance activity, resulting in superior efficacy in activity studies.

[0136] In some embodiments, the CD3 binding domain of the BCMA trispecific antigen binding protein has an affinity for CD3 on cells expressing CD3 with a K D is 1000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In some embodiments, the CD3 binding domain of the BCMA trispecific antigen binding protein has an affinity for CD3ε, CD3γ, or CD3δ with a K D In a further embodiment, the CD3 binding domain of the BCMA trispecific antigen binding protein has a low affinity for CD3, i.e., about 100 nM or more.

[0137] The affinity for binding to CD3 can be determined by, for example, the ability of the BCMA trispecific antigen binding protein itself or its CD3 binding domain to bind to CD3 coated on an assay plate, CD3 displayed on the surface of a microbial cell, CD3 in a solution, etc. The binding activity of the BCMA trispecific antigen binding protein itself or its CD3 binding domain to CD3 of the present disclosure can be determined as follows: a ligand (e.g., CD3) or the BCMA trispecific antigen binding protein itself or its CD3 binding domain is immobilized to beads, a substrate, a cell, etc. The reagents can be added to a suitable buffer and the binding partners can be incubated at a given temperature for a period of time. After washing to remove unbound substances, the bound protein can be released using, for example, SDS, a high pH buffer, etc., and analyzed by, for example, surface plasmon resonance (SPR).

[0138] Half-life extension domain

[0139] Concerning domains that extend the half-life of antigen binding domains, it is contemplated that such domains include, but are not limited to, albumin binding domains, Fc domains, small molecules, and other half-life extension domains known in the art.

[0140] Human albumin (ALB) (molecular weight approximately 67 kDa) is the most abundant protein in plasma, present at approximately 50 mg / ml (600 μM), and has a half-life of approximately 20 days in humans. ALB serves to maintain plasma pH, contributes to colloid blood pressure, acts as a carrier for many metabolites and fatty acids, and serves as the major drug transporter in plasma.

[0141] Non-covalent association with albumin prolongs the elimination half-life of short-lived proteins. For example, recombinant fusions of albumin binding domains with Fab fragments resulted in 25-fold and 58-fold increased in vivo clearance and 26-fold and 37-fold increased half-life when administered intravenously to mice and rabbits, respectively, compared to administration of the Fab fragment alone. In another example, when insulin was acylated with fatty acids to promote association with albumin, a prolonged effect was observed when injected subcutaneously in rabbits or pigs. In summary, these studies demonstrate a link between albumin binding and a prolonged effect.

[0142] In one aspect, the BCMA targeting trispecific protein described herein comprises a half-life extension domain, such as a domain that specifically binds to ALB. In some embodiments, the ALB binding domain of the BCMA trispecific antigen binding protein can be any domain that binds to ALB, including but not limited to domains from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, and humanized antibodies. In some embodiments, the ALB binding domain is a single-chain variable fragment (scFv) specific for HSA, a single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL), and a variable domain (VHH) of a single-domain antibody from a camelid family, a peptide, a ligand, or a small molecule entity. In certain embodiments, the ALB binding domain is a single-domain antibody. In other embodiments, the ALB binding domain is a peptide. In further embodiments, the ALB binding domain is a small molecule. In some embodiments, it is envisioned that the HSA binding domain of the BCMA trispecific antigen binding protein is quite small and does not exceed 25kD, does not exceed 20kD, does not exceed 15kD, or does not exceed 10kD. In certain instances, the ALB binding protein, if a peptide or small molecule entity, is 5 kD or less.

[0143] The half-life extension domain of the BCMA trispecific antigen binding protein causes pharmacodynamic and pharmacokinetic changes in the BCMA trispecific antigen binding protein itself. As described above, the half-life extension domain extends the elimination half-life. The half-life extension domain also changes the pharmacodynamic properties, including changes in the tissue distribution, penetration and diffusion of the trispecific antigen binding protein. In some embodiments, the half-life extension domain provides improved tissue (including tumor) targeting, tissue distribution, tissue penetration, diffusion within the tissue and enhanced efficacy compared to proteins without half-life extension domains. In one embodiment, the treatment method effectively and efficiently utilizes a reduced amount of trispecific antigen binding proteins, thereby resulting in reduced side effects, such as reduced cytotoxicity of non-tumor cells.

[0144] In addition, the binding affinity of the half-life extension domain can be selected so as to target a specific elimination half-life in a specific trispecific antigen-binding protein. Therefore, in some embodiments, the half-life extension domain has a high binding affinity. In other embodiments, the half-life extension domain has a medium binding affinity. In other embodiments, the half-life extension domain has a low or tiny binding affinity. Exemplary binding affinities include KD concentrations of 10nM or less (high), 10nM to 100nM (medium), and greater than 100nM (low). As described above, the binding affinity to ALB is determined by known methods such as surface plasmon resonance (SPR).

[0145] In some embodiments, the ALB binding domain described herein comprises a single domain antibody. B cell maturation antigen (BCMA) binding domain

[0146] B cell maturation antigen (BCMA, TNFRSF17, CD269) is a transmembrane protein belonging to the tumor necrosis family receptor (TNFR) superfamily, which is mainly expressed on terminally differentiated B cells. BCMA expression is confined to the B cell lineage, mainly present in plasma cells and plasmablasts, and to a certain extent present in memory B cells, but actually does not exist in peripheral and immature B cells. BCMA is also expressed on multiple myeloma (MM) cells, leukemia cells and lymphoma cells.

[0147] BCMA was identified by molecular analysis of the t(4;16)(q26;p13) translocation found in human intestinal T-cell lymphoma and the in-frame sequence was mapped to chromosome band 16p13.1.

[0148] The human BCMA cDNA has an open reading frame of 552 bp encoding a polypeptide of 184 amino acids. The BCMA gene is organized into three exons separated by two introns, each flanked by GT donor and AG acceptor consensus splice sites, and encodes a 1.2 kb transcript. The structure of the BCMA protein includes an entire transmembrane protein based on a central hydrophobic region of 24 amino acids in an alpha-helical structure.

[0149] The mouse BCMA gene is located on chromosome 16 that is syntenic to the human 16p13 region and also includes three exons separated by two introns. The gene encodes a protein of 185 amino acids. Mouse BCMA mRNA is expressed as a 404 bp transcript at the highest level in plasmacytoma cells (J558) and at a moderate level in the A20 B cell lymphoma cell line. In contrast to human cell lines of T cell and dendritic cell origin, low levels of mouse BCMA mRNA transcripts were also detected in T cell lymphoma (EL4, BW5147) and dendritic cell (CB1D6, D2SC1) lines. The mouse BCMA cDNA sequence has 69.3% nucleotide identity with the human BCMA cDNA sequence, and when the coding regions between the two cDNA sequences are compared, there is a slightly higher identity (73.7%). The mouse BCMA protein is 62% identical to the human BCMA protein and, like human BCMA, contains a hydrophobic region that may be an internal transmembrane segment. Both the mouse and human BCMA proteins have six conserved cysteine ​​residues in the N-terminal 40-amino acid domain, which is consistent with the formation of a cysteine ​​repeat motif found in the extracellular domain of TNFR. Similar to TNFR superfamily members, the BCMA protein contains a conserved aromatic residue located 4 to 6 residues C-terminal to the first cysteine.

[0150] BCMA is not expressed on the cell surface but is localized to the Golgi apparatus. The amount of BCMA expressed is proportional to the stage of cell differentiation (highest in plasma cells).

[0151] It is involved in B-cell development and homeostasis due to its interaction with its ligands BAFF (B-cell activating factor, also known as TALL-1 or TNFSF13B) and APRIL (proliferation-inducing ligand).

[0152] BCMA, together with its family members TACI (transmembrane activator and cyclophilin ligand interactor) and BAFF-R (B-cell activating factor receptor, also known as tumor necrosis factor receptor superfamily member 13C), regulates different aspects of humoral immunity, B-cell development and homeostasis. BCMA expression occurs at a fairly late stage of B-cell differentiation and contributes to the long-term survival of plasmablasts and plasma cells in the bone marrow. BCMA also supports the growth and survival of multiple myeloma (MM) cells.

[0153] BCMA is widely known for its functional activity in mediating plasma cell survival that maintains long-term humoral immunity.

[0154] There is a need to have treatment options for solid tumor diseases associated with overexpression of BCMA, such as the cancers multiple myeloma, leukemia, and lymphoma. In certain embodiments, the present disclosure provides single domain proteins that specifically bind to BCMA on the surface of tumor target cells.

[0155] The design of the BCMA-targeted trispecific proteins described herein allows the BCMA binding domain to be flexible because the BCMA binding domain can be any type of binding domain, including but not limited to domains from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, and humanized antibodies. In some embodiments, the BCMA binding domain is a single-chain variable fragment (scFv), a single-domain antibody, such as a heavy chain variable domain (VH), a light chain variable domain (VL), and a variable domain (VHH) of a single-domain antibody from camelid origin. In other embodiments, the BCMA binding domain is a non-Ig binding domain, i.e., an antibody mimetic, such as anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, DARPins, fynomers, kunitz domain peptides, and monobodies. In further embodiments, the BCMA binding domain is a ligand or peptide that binds or associates with BCMA. In further embodiments, the BCMA binding domain is a knottin. In further embodiments, the BCMA binding domain is a small molecule entity.

[0156] In some embodiments, the BCMA-binding domain binds to a protein comprising the sequence of SEQ ID NO: 469, 470, or 471. In some embodiments, the BCMA-binding domain binds to a protein comprising a truncated sequence compared to SEQ ID NO: 469, 470, or 471.

[0157] In some embodiments, the BCMA binding domain is an anti-BCMA antibody or antibody variant. As used herein, the term "antibody variant" refers to variants and derivatives of the antibodies described herein. In certain embodiments, it is related to amino acid sequence variants of the anti-BCMA antibodies described herein. For example, in certain embodiments, it is expected that the amino acid sequence variants of the anti-BCMA antibodies described herein improve the binding affinity and / or other biological properties of the antibodies. Exemplary methods for preparing amino acid variants include, but are not limited to, introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequence of the antibody.

[0158] Any combination of deletion, insertion and substitution can be performed to obtain the final construct, provided that the final construct has the desired characteristics, such as antigen binding. In certain embodiments, antibody variants with one or more amino acid substitutions are provided. The sites of interest for substitution mutagenesis include CDR and framework regions. Examples of such substitutions are described below. Amino acid substitutions can be introduced into the antibody of interest, and for desired activity, for example, retained / improved antigen binding, reduced immunogenicity or improved T cell-mediated cytotoxicity (TDCC). Conservative and non-conservative amino acid substitutions are considered for the preparation of antibody variants.

[0159] In another example of substitutions used to generate variant anti-BCMA antibodies, one or more hypervariable region residues of a parent antibody are substituted. Typically, variants are then selected based on improvements in desired properties compared to the parent antibody, e.g., increased affinity, decreased affinity, decreased immunogenicity, increased pH dependence of binding.

[0160] In some embodiments, the BCMA binding domain of the BCMA targeting trispecific protein is a single domain antibody, such as a heavy chain variable domain (VH) specific for BCMA, a variable domain (VHH) of a llama-derived sdAb, a peptide, a ligand, or a small molecule entity. In some embodiments, the BCMA binding domain of the BCMA targeting trispecific protein described herein is any domain that binds to BCMA, including but not limited to domains from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, and humanized antibodies. In certain embodiments, the BCMA binding domain is a single domain antibody. In other embodiments, the BCMA binding domain is a peptide. In further embodiments, the BCMA binding domain is a small molecule.

[0161] Generally, it should be noted that the term single domain antibody, as used herein in its broadest sense, is not limited to a specific biological source or a specific method of preparation. A single domain antibody is an antibody whose complementary determining region is a part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies that are naturally free of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies, and single domain scaffolds different from those derived from antibodies. A single domain antibody can be any single domain antibody in the art, or any future single domain antibody. Single domain antibodies can be derived from any species, including but not limited to mice, humans, camels, llamas, goats, rabbits, cattle. For example, in some embodiments, the single domain antibodies of the present disclosure are obtained by the following methods: (1) by isolating the VHH domain of a naturally occurring heavy chain antibody; (2) by expressing a nucleotide sequence encoding a naturally occurring VHH domain; (3) by "humanization" of a naturally occurring VHH domain or by expressing a nucleic acid encoding such a humanized VHH domain; (4) by "camelization" of a naturally occurring VH domain from any animal species, in particular from a mammalian species, such as from humans, or by expressing a nucleic acid encoding such a camelized VH domain; (5) by "camelization" of a "domain antibody" or "Dab", or by expressing a nucleic acid encoding such a camelized VH domain; (6) by preparing a protein, polypeptide or other amino acid sequence using synthetic or semi-synthetic techniques; (7) by preparing a nucleic acid encoding a single domain antibody using nucleic acid synthesis techniques known in the art, and then expressing the nucleic acid obtained thereby; and / or (8) by any combination of one or more of the foregoing.

[0162] In one embodiment, the single-domain antibody corresponds to the VHH domain of a naturally occurring heavy chain antibody against BCMA. As further described herein, such VHH sequences can generally be generated or obtained by appropriately immunizing a llama species with BCMA (i.e., to generate an immune response and / or heavy chain antibodies against BCMA), obtaining a suitable biological sample (such as a blood sample, a serum sample, or a B cell sample) from the llama, and generating a VHH sequence against BCMA starting from the sample using any suitable technique known in the art.

[0163] In another embodiment, such naturally occurring VHH domains against BCMA are obtained from a naive library of Camelidae VHH sequences, for example by screening such a library using BCMA or at least one part, fragment, antigenic determinant or epitope thereof using one or more screening techniques known in the art. Such libraries and techniques are described, for example, in WO 99 / 37681, WO 01 / 90190, WO 03 / 025020 and WO 03 / 035694. Alternatively, an improved synthetic or semisynthetic library derived from a naive VHH library is used, such as a VHH library obtained from a naive VHH library by techniques such as random mutagenesis and / or CDR shuffling, for example as described in WO 00 / 43507.

[0164] In a further embodiment, yet another technique for obtaining VHH sequences against BCMA involves appropriately immunizing a transgenic mammal capable of expressing heavy chain antibodies (i.e., to generate an immune response and / or heavy chain antibodies against BCMA), obtaining a suitable biological sample (such as a blood sample, a serum sample, or a B cell sample) from the transgenic mammal, and then generating VHH sequences against BCMA starting from the sample using any suitable technique known in the art. For example, rats or mice expressing heavy chain antibodies and other methods and techniques described in WO 02 / 085945 and WO 04 / 049794 can be used for this purpose.

[0165] In some embodiments, the BCMA targeting trispecific protein anti-BCMA single domain antibody includes a single domain antibody having an amino acid sequence corresponding to the amino acid sequence of a naturally occurring VHH domain, but has been "humanized", i.e., by replacing one or more amino acid residues in the amino acid sequence of the naturally occurring VHH sequence (particularly in the framework sequence) with one or more amino acid residues present at the corresponding position in the VH domain of a conventional 4-chain antibody from a human (e.g., as described above). This can be done in a manner known in the art, which will be apparent to a person skilled in the art, for example based on the further description herein. In addition, it should be noted that such humanized anti-BCMA single domain antibodies of the present disclosure are obtained in any suitable manner known per se (i.e., as indicated in points (1)-(8) above), and are therefore not strictly limited to polypeptides obtained using polypeptides comprising naturally occurring VHH domains as starting materials. In some additional embodiments, the single domain anti-BCMA antibodies as described herein include single domain antibodies having an amino acid sequence corresponding to the amino acid sequence of a naturally occurring VH domain, but having been "camelized", i.e., by replacing one or more amino acid residues in the amino acid sequence of a naturally occurring VH domain from a conventional 4-chain antibody with one or more amino acid residues present at the corresponding positions in the VHH domain of a heavy chain antibody. Such "camelization" substitutions are preferably inserted at amino acid positions that form the VH-VL interface and / or are present at the VH-VL interface and / or at the so-called Camelidae Hallmark residues (see, e.g., WO 94 / 04678, and Davies and Riechmann (1994 and 1996)). Preferably, the VH sequence used as the starting material or starting point for generating or designing a camelized single domain is preferably a VH sequence from a mammal, more preferably a human VH sequence, such as a VH3 sequence. However, it should be noted that in certain embodiments, such camelized anti-BCMA single domain antibodies of the present disclosure are obtained in any suitable manner known in the art (i.e., as indicated in points (1)-(8) above), and are therefore not strictly limited to polypeptides obtained using polypeptides comprising a naturally occurring VH domain as starting material. For example, as further described herein, both "humanization" and "camelization" are performed by providing a nucleotide sequence encoding a naturally occurring VHH domain or VH domain, respectively, and then changing one or more codons in the nucleotide sequence in such a way that the new nucleotide sequence encodes a "humanized" or "camelized" single domain antibody, respectively. The nucleic acid can then be expressed to provide the desired anti-BCMA single domain antibody of the present disclosure.Alternatively, in other embodiments, the amino acid sequence of the desired humanized or camelized anti-BCMA single domain antibody of the present disclosure is designed based on the amino acid sequence of the naturally occurring VHH domain or VH domain, respectively, and then synthesized de novo using known peptide synthesis techniques. In some embodiments, the nucleotide sequence encoding the desired humanized or camelized anti-BCMA single domain antibody of the present disclosure is designed based on the amino acid sequence or nucleotide sequence of the naturally occurring VHH domain or VH domain, respectively, and then synthesized de novo using known nucleic acid synthesis techniques, and then the nucleic acid obtained thereby is expressed using known expression techniques to provide the desired anti-BCMA single domain antibody of the present disclosure.

[0166] Other suitable methods and techniques for obtaining the anti-BCMA single domain antibodies of the present disclosure and / or nucleic acids encoding the same starting from naturally occurring VH sequences or VHH sequences include, for example, combining one or more portions of one or more naturally occurring VH sequences (such as one or more framework (FR) sequences and / or complementarity determining region (CDR) sequences), one or more portions of one or more naturally occurring VHH sequences (such as one or more FR sequences or CDR sequences), and / or one or more synthetic or semi-synthetic sequences in a suitable manner to provide the anti-BCMA single domain antibodies of the present disclosure or nucleotide sequences or nucleic acids encoding the same.

[0167] In some embodiments, the BCMA binding domain is an anti-BCMA specific antibody comprising a heavy chain variable complementary determining region CDR1, a heavy chain variable CDR2, a heavy chain variable CDR3, a light chain variable CDR1, a light chain variable CDR2, and a light chain variable CDR3. In some embodiments, the BCMA binding domain comprises any domain that binds to BCMA, including but not limited to domains from: monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, or antigen binding fragments such as single domain antibodies (sdAb), Fab, Fab', F(ab)2, and Fv fragments, fragments consisting of one or more CDRs, single chain antibodies (e.g., single chain Fv fragments (scFv)), disulfide bond stabilized Fv (dsFv) fragments, heteroconjugate antibodies (e.g., bispecific antibodies), pFv fragments, heavy chain monomers or dimers, light chain monomers or dimers, and dimers consisting of one heavy chain and one light chain. In some embodiments, the BCMA binding domain is a single domain antibody. In some embodiments, an anti-BCMA single domain antibody comprises a heavy chain variable complementarity determining region (CDR), CDR1, CDR2, and CDR3.

[0168] In some embodiments, a BCMA-binding protein of the present disclosure is a polypeptide comprising an amino acid sequence consisting of four framework regions / sequences (f1-f4) interrupted by three complementarity determining regions / sequences, as shown in the following formula: f1-r1-f2-r2-f3-r3-f4, wherein r1, r2, and r3 are complementarity determining regions CDR1, CDR2, and CDR3, respectively, and f1, f2, f3, and f4 are framework residues. The r1 residues of the BCMA-binding proteins of the present disclosure include, for example, amino acid residues 26, 27, 28, 29, 30, 31, 32, 33, and 34; the r2 residues of the BCMA-binding proteins of the present disclosure include, for example, amino acid residues such as 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, and 63; and the r3 residues of the BCMA-binding proteins of the present disclosure include, for example, amino acid residues such as 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, and 108. In some embodiments, the BCMA-binding protein comprises an amino acid sequence selected from SEQ ID NOs: 346-460.

[0169] In one embodiment, the CDR1 does not comprise the amino acid sequence of SEQ ID NO: 599. In one embodiment, the CDR2 does not comprise the amino acid sequence of SEQ ID NO: 600. In one embodiment, the CDR3 does not comprise the amino acid sequence of SEQ ID NO: 601.

[0170] In some embodiments, the CDR1 comprises the amino acid sequence as shown in SEQ ID NO:1, or a variant thereof having one, two, three, four, five, six, seven, eight, nine or ten amino acid substitutions. An exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:4. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:5. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:6. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:7. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:8. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:9. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:10. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:11. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:12. Another exemplary CDR1 comprises the amino acid sequence as shown in SEQ ID NO:13. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:14. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:15. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:16. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:17. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:18. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:19. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:20. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:21. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:22. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:23. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:24. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:25. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 28. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 29.Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:30. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:31. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:32. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:33. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:34. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:35. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:36. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:37. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:38. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:39. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:40. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:41. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:42. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:43. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:44. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:45. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:46. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:47. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:48. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:49. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:50. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:51. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:52. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:53. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 54. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 55. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 56. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 57.Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:58. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:59. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:60. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:61. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:62. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:63. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:64. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:65. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:66. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:67. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:68. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:69. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:70. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:71. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:72. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:73. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:74. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:75. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:76. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:77. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:78. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:79. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:80. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:81. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 82. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 83. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 84. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 85.Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:86. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:87. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:88. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:89. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:90. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:91. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:92. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:93. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:94. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:95. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:96. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:97. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:98. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:99. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:100. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:101. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:102. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:103. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:104. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:105. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:106. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:107. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:108. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO:109. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 110. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 111. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 112. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 113.Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 114. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 115. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 116. Another exemplary CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 117.

[0171] In some embodiments, the CDR2 comprises the sequence as set forth in SEQ ID NO:2, or a variant having one, two, three, four, five, six, seven, eight, nine or ten amino acid substitutions in SEQ ID NO:2. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:118. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:119. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:120. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:121. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:122. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:123. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:124. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:125. Another exemplary CDR2 comprises the amino acid sequence as set forth in SEQ ID NO:126. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:127. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:128. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:129. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:130. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:131. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:132. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:133. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:134. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:135. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:136. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:137. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:138. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 139. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 140. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 141. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 142.Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 143. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 144. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 145. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 146. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 147. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 148. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 149. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 150. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 151. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 152. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 153. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 154. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 155. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 156. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 157. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 158. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 159. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 160. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 161. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 162. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 163. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 164. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 165. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 166. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 167. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 168. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 169.Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 170. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 171. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 172. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 173. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 174. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 175. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 176. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 177. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 178. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 179. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 180. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 181. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 182. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 183. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 184. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 185. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 186. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 187. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 188. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 189. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 190. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 191. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 192. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 193. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 194. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 195. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 196.Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:197. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:198. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:199. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:200. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:201. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:202. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:203. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:204. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:205. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:206. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:207. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:208. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:209. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:210. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:211. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:212. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:213. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:214. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:215. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:216. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:217. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:218. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:219. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:220. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 222. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 223.Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:224. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:225. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:226. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:227. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:228. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:229. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:230. Another exemplary CDR2 comprises the amino acid sequence set forth in SEQ ID NO:231.

[0172] In some embodiments, the CDR3 comprises the sequence as set forth in SEQ ID NO:3, or a variant having one, two, three, four, five, six, seven, eight, nine or ten amino acid substitutions in SEQ ID NO:3. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:232. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:233. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:234. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:235. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:236. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:237. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:238. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:239. Another exemplary CDR3 comprises the amino acid sequence as set forth in SEQ ID NO:240. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:241. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:242. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:243. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:244. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:245. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:246. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:247. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:248. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:249. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:250. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:251. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:252. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 253. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 254. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 255. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 256.Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:257. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:258. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:259. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:260. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:261. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:262. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:263. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:264. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:265. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:266. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:267. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:268. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:269. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:270. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:271. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:272. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:273. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:274. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:275. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:276. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:277. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:278. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:279. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:280. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 281. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 282. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 283.Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:284. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:285. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:286. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:287. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:288. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:289. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:290. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:291. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:292. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:293. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:294. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:295. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:296. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:297. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:298. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:299. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:300. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:301. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:302. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:303. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:304. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:305. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:306. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:307. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 308. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 309. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 310.Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:311. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:312. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:313. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:314. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:315. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:316. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:317. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:318. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:319. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:320. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:321. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:322. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:323. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:324. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:325. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:326. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:327. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:328. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:329. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:330. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:331. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:332. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:333. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:334. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 335. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 336. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 337.Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:338. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:339. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:340. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:341. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:342. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:343. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:344. Another exemplary CDR3 comprises the amino acid sequence set forth in SEQ ID NO:345.

[0173] In various embodiments, the BCMA-binding proteins of the present disclosure have a CDR1 having an amino acid sequence that is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID NOs:4-117.

[0174] In various embodiments, the BCMA-binding proteins of the present disclosure have a CDR2 having an amino acid sequence that is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID NOs: 118-231.

[0175] In various embodiments, the complementarity determining region of a BCMA-binding protein of the present disclosure has a CDR3 having an amino acid sequence that is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID NOs: 232-345.

[0176] In various embodiments, the BCMA-binding proteins of the present disclosure have an amino acid sequence that is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID NOs: 346-460.

[0177] In various embodiments, the BCMA-binding proteins of the present disclosure have a framework 1 (f1) having an amino acid sequence that is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO:461 or SEQ ID NO:462.

[0178] In various embodiments, the BCMA-binding proteins of the present disclosure have a framework 2 (f2) having an amino acid sequence that is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO:463.

[0179] In various embodiments, the BCMA-binding proteins of the present disclosure have a framework 3 (f3) having an amino acid sequence that is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO:464 or SEQ ID NO:465.

[0180] In various embodiments, the BCMA-binding proteins of the present disclosure have a framework 4 (f4) having an amino acid sequence that is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO:466 or SEQ ID NO:467.

[0181] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 346. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 347. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 348. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 349. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 350. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 351. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 352. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 353. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 354. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 355. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 356. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 357. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 358. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 359.

[0182] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 360. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 361. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 362. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 363. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 364. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 365. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 366. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 367. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 368. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:369.

[0183] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 370. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 371. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 372. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 373. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 374. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 375. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 376. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 377. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 378. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:379.

[0184] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 380. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 381. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 382. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 383. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 384. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 385. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 386. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 387. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 388. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:389.

[0185] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 390. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 391. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 392. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 393. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 394. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 395. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 396. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 397. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 398. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:399.

[0186] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 400. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 401. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 402. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 403. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 404. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 405. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 406. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 407. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 408. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:409.

[0187] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 410. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 411. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 412. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 413. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 414. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 415. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 416. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 417. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 418. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:419.

[0188] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 420. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 421. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 422. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 423. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 424. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 425. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 426. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 427. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 428. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:429.

[0189] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 430. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 431. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 432. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 433. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 434. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 435. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 436. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 437. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 438. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:439.

[0190] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 440. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 441. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 442. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 443. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 444. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 445. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 446. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 447. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 448. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO:449.

[0191] In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 450. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 451. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 452. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 453. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 454. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 455. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 456. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 457. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 458. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 459. In some embodiments, the BCMA-binding protein is a single domain antibody comprising the sequence of SEQ ID NO: 460.

[0192] The BCMA binding proteins described herein are capable of binding to human BCMA with an hKd in the range of about 0.1 nM to about 500 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 450 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 400 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 350 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 300 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 250 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 200 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 150 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 100 nM. In some embodiments, the hKd is in the range of about 0.1 nM to about 90 nM. In some embodiments, the hKd is in the range of about 0.2nM to about 80nM. In some embodiments, the hKd is in the range of about 0.3nM to about 70nM. In some embodiments, the hKd is in the range of about 0.4nM to about 50nM. In some embodiments, the hKd is in the range of about 0.5nM to about 30nM. In some embodiments, the hKd is in the range of about 0.6nM to about 10nM. In some embodiments, the hKd is in the range of about 0.7nM to about 8nM. In some embodiments, the hKd is in the range of about 0.8nM to about 6nM. In some embodiments, the hKd is in the range of about 0.9nM to about 4nM. In some embodiments, the hKd is in the range of about 1nM to about 2nM.

[0193] In some embodiments, any of the aforementioned BCMA binding domains is an affinity peptide tagged for ease of purification. In some embodiments, the affinity peptide tag is six consecutive histidine residues, also known as a His tag or 6X-his (His-His-His-His-His; SEQ ID NO: 471).

[0194] In certain embodiments, the BCMA binding domain of the present disclosure preferentially binds to membrane-bound BCMA relative to soluble BCMA. Membrane-bound BCMA refers to the presence of BCMA in or on the cell membrane surface of cells expressing BCMA. Soluble BCMA refers to BCMA that is no longer present in or on the cell membrane surface of cells expressing or expressing BCMA. In some cases, soluble BCMA is present in the blood and / or lymphatic circulation of the subject. In one embodiment, the binding of the BCMA binding domain to membrane-bound BCMA is at least 5 times, 10 times, 15 times, 20 times, 25 times, 30 times, 40 times, 50 times, 100 times, 500 times or 1000 times that of the binding to soluble BCMA. In one embodiment, the BCMA-targeted trispecific antigen-binding protein of the present disclosure preferentially binds to membrane-bound BCMA, which is 30 times that of the binding to soluble BCMA. The preferential binding of antigen-binding proteins to membrane-bound BCMA relative to soluble BCMA can be easily determined using assays known in the art.

[0195] Trispecific protein

[0196] The BCMA-binding trispecific protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 483-597.

[0197] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 483. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 484. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 485. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 486. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 487. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 488. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 489. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 490. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 491. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 492. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 493. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 494. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 495. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 496. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 497. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 498. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 499.

[0198] In one embodiment, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 500. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 501. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 502. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 503. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 504. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 505. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 506. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 507. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 508. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 509.

[0199] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 510. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 511. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 512. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 513. In one embodiment, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 514. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 515. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 516. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 517. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 518. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 519.

[0200] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 520. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 521. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 522. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 523. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 524. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 525. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 526. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 527. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 528. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 529.

[0201] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 530. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 531. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 532. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 533. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 534. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 535. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 536. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 537. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 538. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 539. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 540.

[0202] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 541. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 542. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 543. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 544. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 545. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 546. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 547. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 5048. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 549. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 550.

[0203] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 551. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 552. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 553. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 554. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 555. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 556. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 557. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 558. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 559.

[0204] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 560. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 561. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 562. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 563. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 564. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 565. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 566. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 567. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 568. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 569.

[0205] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 570. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 571. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 572. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 573. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 574. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 575. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 576. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 577. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 578. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 579.

[0206] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 580. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 581. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 582. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 583. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 584. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 585. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 586. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 587. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 588. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 589.

[0207] In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 590. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 591. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 592. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 593. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 594. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 595. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 596. In one example, the BCMA binding trispecific protein comprises the amino acid sequence of SEQ ID NO: 597.

[0208] Polynucleotides encoding BCMA-targeting trispecific proteins

[0209] In some embodiments, polynucleotide molecules encoding the anti-BCMA trispecific binding proteins described herein are also provided. In some embodiments, the polynucleotide molecules are provided in the form of DNA constructs. In other embodiments, the polynucleotide molecules are provided in the form of messenger RNA transcripts.

[0210] The polynucleotide molecules are constructed by known methods, for example, by combining genes encoding three binding domains separated by peptide connectors, or in other embodiments, directly linked by peptide bonds to a single genetic construct operably linked to a suitable promoter and optionally a suitable transcription terminator, and expressed in bacteria or other suitable expression systems such as CHO cells. In embodiments where the BCMA binding domain is a small molecule, the polynucleotide contains genes encoding a CD3 binding domain and a half-life extension domain. In embodiments where the half-life extension domain is a small molecule, the polynucleotide contains genes encoding domains that bind to CD3 and BCMA. Depending on the vector system and host utilized, any number of suitable transcription and translation elements may be used, including constitutive and inducible promoters. The promoter is selected so that it drives expression of the polynucleotide in the corresponding host cell.

[0211] In some embodiments, the polynucleotide is inserted into a vector, preferably an expression vector, which represents a further embodiment. The recombinant vector can be constructed according to known methods. Vectors of particular interest include plasmids, phagemids, phage derivatives, viruses (virii) (e.g., retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, lentiviruses, etc.) and cosmids.

[0212] A variety of expression vector / host systems can be used to contain and express the polynucleotide encoding the polypeptide of the trispecific antigen binding protein. Examples of expression vectors are pSKK (Le Gall et al., J Immunol Methods. (2004) 285(1): 111-27) for expression in E. coli or pcDNA5 (Invitrogen) for expression in mammalian cells.

[0213] Thus, in some embodiments, the BCMA-targeting trispecific proteins as described herein are produced by introducing a vector encoding a protein as described above into a host cell, and culturing the host cell under conditions that allow expression of the protein domains, which can be isolated and optionally further purified.

[0214] Integration into chimeric antigen receptors (CARs)

[0215] In certain examples, the BCMA targeting trispecific antigen binding proteins disclosed herein can be incorporated into chimeric antigen receptors (CAR). Engineered immune effector cells, such as T cells or NK cells, can be used to express CAR, which includes anti-BCMA targeting trispecific proteins containing anti-BCMA single domain antibodies described herein. In one embodiment, the CAR including the anti-BCMA targeting trispecific proteins described herein is connected to the transmembrane domain via the hinge region, and is further connected to the costimulatory domain, for example, obtained from OX40, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278) or 4-1BB functional signaling domains. In some embodiments, the CAR further includes sequences encoding intracellular signaling domains such as 4-1BB and / or CD3ζ.

[0216] BCMA trispecific protein modification

[0217] The BCMA-targeting trispecific proteins described herein include derivatives or analogs in which (i) amino acids are replaced with amino acid residues that are not encoded by the genetic code, (ii) the mature polypeptide is fused to another compound such as polyethylene glycol, or (iii) additional amino acids are fused to the protein, such as a leader sequence or a secretory sequence or a sequence for purifying the protein.

[0218] Typical modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer RNA-mediated addition of amino acids to proteins such as arginylation and ubiquitination.

[0219] Modifications are made at any position in the BCMA-targeted trispecific proteins described herein, including the peptide backbone, amino acid side chains, and amino or carboxyl termini. Certain common peptide modifications that can be used to modify BCMA-targeted trispecific proteins include glycosylation, lipid attachment, sulfation, γ-carboxylation of glutamic acid residues, hydroxylation, blocking of the amino or carboxyl groups or both in the polypeptide by covalent modification, and ADP-ribosylation.

[0220] Pharmaceutical composition

[0221] In some embodiments, a pharmaceutical composition is also provided, which comprises an anti-BCMA trispecific binding protein described herein, a vector comprising a polynucleotide encoding a polypeptide of the BCMA targeting trispecific protein or a host cell transformed by the vector, and at least one pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the component and is non-toxic to the patient to which it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions such as oil-in-water emulsions, various types of wetting agents, sterile solutions, and the like. Such carriers can be formulated by conventional methods and can be administered to a subject at a suitable dose. Preferably, the composition is sterile. These compositions may also contain excipients such as preservatives, emulsifiers, and dispersants. Various antibacterial and antifungal agents may be included to ensure that the action of microorganisms is prevented. Another embodiment provides one or more of the above-mentioned BCMA targeting trispecific proteins, which are packaged in a lyophilized form or in an aqueous medium.

[0222] In some embodiments of the pharmaceutical composition, the BCMA targeting trispecific protein described herein is encapsulated in a nanoparticle. In some embodiments, the nanoparticle is a fullerene, a liquid crystal, a liposome, a quantum dot, a superparamagnetic nanoparticle, a dendrimer, or a nanorod. In other embodiments of the pharmaceutical composition, the BCMA trispecific antigen binding protein is attached to a liposome. In some cases, the BCMA trispecific antigen binding protein is conjugated to the surface of the liposome. In some cases, the BCMA trispecific antigen binding protein is encapsulated in the shell of the liposome. In some cases, the liposome is a cationic liposome.

[0223] The BCMA-targeted trispecific proteins described herein are contemplated for use as drugs. Administration is achieved in different ways, for example, by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. In some embodiments, the route of administration depends on the type of therapy and the type of compound contained in the pharmaceutical composition. The dosing regimen will be determined by the attending physician based on other clinical factors. The dosage for any one patient depends on many factors, including patient size, body surface area, age, sex, specific compound to be administered, time and route of administration, type of therapy, overall health and other concurrently administered drugs. An "effective dose" refers to the amount of active ingredient that is sufficient to affect the course and severity of the disease, thereby resulting in mitigation or alleviation of this pathology, and can be determined using known methods.

[0224] In some embodiments, the BCMA-targeted trispecific proteins of the present disclosure are administered at a dose of up to 10 mg / kg at a frequency of once a week. In some cases, the dosage range is from about 1 ng / kg to about 10 mg / kg. In some embodiments, the dosage is from about 1 ng / kg to about 10 ng / kg, from about 5 ng / kg to about 15 ng / kg, from about 12 ng / kg to about 20 ng / kg, from about 18 ng / kg to about 30 ng / kg, from about 25 ng / kg to about 50 ng / kg, from about 35 ng / kg to about 60 ng / kg, from about 45 ng / kg to about 70 ng / kg, from about 65 ng / kg to about 85 ng / kg, from about 80 ng / kg to about 1 μg / kg, from about 0.5 μg / kg, from about 1 μg / kg, from about 2 μg / kg, from about 3 μg / kg, from about 4 μg / kg, from about 5 μg / kg, from about 6 μg / kg, from about 7 μg / kg, from about 8 μg / kg, from about 9 μg / kg, from about 10 μg / kg, from about 11 μg / kg, from about 12 μg / kg, from about 13 μg / kg, from about 14 μg / kg, from about 15 μg / kg, from about 16 μg / kg, from about 18 μg / kg, from about 19 μg / kg, from about 20 μg / kg, from about 21 μg / kg, from about 22 μg / kg, from about 24 μg / kg, from about 25 μg / kg, from about 26 μg / kg, from about 28 μg / kg, from about 29 μg / kg, from about 30 μg / kg g / kg to about 5 μg / kg, about 2 μg / kg to about 10 μg / kg, about 7 μg / kg to about 15 μg / kg, about 12 μg / kg to about 25 μg / kg, about 20 μg / kg to about 50 μg / kg, about 35 μg / kg to about 70 μg / kg, about 45 μg / kg to about 80 μg / kg, about 65 μg / kg to about 90 μg / kg, about 85 μg / kg to about 0.1 mg / kg, about 0.095 mg / kg to about 10 mg / kg. In some cases, the dosage is about 0.1 mg / kg to about 0.2 mg / kg, about 0.25 mg / kg to about 0.5 mg / kg, about 0.45 mg / kg to about 1 mg / kg, about 0.75 mg / kg to about 3 mg / kg, about 2.5 mg / kg to about 4 mg / kg, about 3.5 mg / kg to about 5 mg / kg, about 4.5 mg / kg to about 6 mg / kg, about 5.5 mg / kg to about 7 mg / kg, about 6.5 mg / kg to about 8 mg / kg, about 7.5 mg / kg to about 9 mg / kg, or about 8.5 mg / kg to about 10 mg / kg. In some embodiments, the dosage is about less than once a day, once every other day, less than once a day, twice a week, once a week, once every 7 days, once every two weeks, once every two weeks, once every three weeks, once every four weeks, or once a month. In some cases, the dosage is once a week. In some cases, the dosage is once a week, and the dosage is up to 10 mg / kg. In some cases, administration duration is from about 1 day to about 4 weeks or longer.

[0225] Treatment

[0226] In certain embodiments, when administered to a subject with tumor cells expressing BCMA, the BCMA-targeted trispecific proteins of the present disclosure reduce the growth of tumor cells in vivo. The measurement of reduced tumor cell growth can be determined by a variety of different methods known in the art. Non-limiting examples include direct measurement of tumor size, measurement of excised tumor masses and comparison with control subjects, measurement by imaging techniques (e.g., CT or MRI) that may or may not use isotopes or luminescent molecules (e.g., luciferase) to enhance analysis, and the like. In a specific embodiment, compared to a control antigen binding agent, the administration of the trispecific proteins of the present disclosure results in a reduction in the in vivo growth of tumor cells of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%, and a reduction in tumor growth of about 100% indicates complete response and tumor disappearance. In a further embodiment, compared to a control antigen binding agent, the administration of the trispecific proteins of the present disclosure results in a reduction in the in vivo growth of tumor cells of about 50-100%, about 75-100% or about 90-100%. In further embodiments, administration of a trispecific protein of the present disclosure results in about 50-60%, about 60-70%, about 70-80%, about 80-90%, or about 90-100% reduction in in vivo growth of tumor cells compared to a control antigen binding agent.

[0227] In some embodiments, the present invention also provides methods and uses for stimulating the immune system of an individual in need thereof, comprising administering an anti-BCMA targeting trispecific protein described herein. In some cases, administration of an anti-BCMA targeting trispecific protein described herein induces and / or maintains cytotoxicity to cells expressing the target antigen.

[0228] In some embodiments, the present invention also provides methods and uses for stimulating the immune system of an individual in need thereof, comprising administering a BCMA-binding protein described herein. In some cases, administration of a BCMA-binding protein described herein induces and / or maintains cytotoxicity to cells expressing a target antigen. In some cases, cells expressing a target antigen are terminally differentiated B cells, which are cancer cells or tumor cells, or metastatic cancer cells or tumor cells.

[0229] Also provided herein are methods and uses for treating a disease, disorder or condition associated with BCMA, comprising administering a BCMA-binding protein described herein or a multispecific binding protein comprising the BCMA-binding protein to an individual in need thereof.

[0230] Diseases, disorders or conditions associated with BCMA include, but are not limited to, cancers of the B-cell lineage or metastasis.

[0231] Cancers that can be treated, prevented, or managed using the BCMA-binding proteins and methods of use of the present disclosure include, but are not limited to, primary cancers or metastatic cancers.

[0232] Examples of such leukemias include, but are not limited to, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), as well as many less common types, such as hairy cell leukemia (HCL), T-cell prolymphocytic leukemia (T-PLL), large granular lymphocytic leukemia, and adult T-cell leukemia, etc. Acute lymphoblastic leukemia (ALL) subtypes to be treated include, but are not limited to, precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt's leukemia, and acute biphenotypic leukemia. Chronic lymphocytic leukemia (CLL) subtypes to be treated include, but are not limited to, B cell prolymphocytic leukemia. Acute myeloid leukemia (AML) subtypes to be treated include, but are not limited to, acute promyelocytic leukemia, acute myeloblastic leukemia, and acute megakaryoblastic leukemia. Chronic myeloid leukemia (CML) subtypes to be treated include, but are not limited to, chronic myelomonocytic leukemia.

[0233] Examples of lymphomas that may be treated using the methods of the present invention include, but are not limited to, Hodgkin's disease, non-Hodgkin's disease, or any subtype of lymphoma.

[0234] Examples of such multiple myeloma include, but are not limited to, multiple myeloma of the bone or other tissues, including, for example, smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, and the like.

[0235] For reviews of such conditions, see Fishman et al., 1985, Medicine, 2nd ed., JB Lippincott Co., Philadelphia, and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books USA, Inc., United States of America.

[0236] In some embodiments, as used herein, "treatment" or "treatment" refers to therapeutic treatment, wherein the purpose is to slow down (mitigate) an undesirable physiological condition, disorder or disease, or to obtain a beneficial or desired clinical result. For the purposes described herein, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; reduction in the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the condition, disorder or disease state; delayed onset or slowed progression of the condition, disorder or disease; improvement of the condition, disorder or disease state; and detectable or undetectable relief (partial or complete) or enhancement or improvement of the condition, disorder or disease. Treatment includes inducing a clinically significant response without excessive levels of side effects. Treatment also includes extending survival compared to the expected survival without treatment. In other embodiments, "treatment" or "treatment" refers to preventive measures, wherein the purpose is, for example, in a person susceptible to the disease (e.g., an individual carrying genetic markers for a disease such as breast cancer), delaying the onset of an undesirable physiological condition, disorder or disease or reducing its severity.

[0237] In some embodiments of the methods described herein, the BCMA-targeted tri-specific proteins as described herein are administered in combination with agents for treating specific diseases, disorders, or conditions. Agents include, but are not limited to, therapies involving antibodies, small molecules (e.g., chemotherapeutic drugs), hormones (steroids, peptides, etc.), radiotherapy (gamma rays, X-rays, and / or directed delivery of radioisotopes, microwaves, UV radiation, etc.), gene therapy (e.g., antisense, retroviral therapy, etc.), and other immunotherapies. In some embodiments, the anti-BCMA-targeted tri-specific proteins described herein are administered in combination with antidiarrheals, antiemetics, analgesics, opioids, and / or nonsteroidal anti-inflammatory agents. In some embodiments, the anti-BCMA-targeted tri-specific proteins described herein are administered in combination with anticancer agents.

[0238] Non-limiting examples of anticancer agents that can be used in various embodiments of the present disclosure, including pharmaceutical compositions and dosage forms and kits of the present disclosure, include: acivicin; aclarubicin; acodazole hydrochloride; aclonine; adolesin; aldesleukin; hexamethylmelamine; ambomycin; ametrine acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; tricline; azacitidine; azatepa; azomycin; batimastat; Benzotepa; Bicalutamide; Bisantrene hydrochloride; Bisantrene dimesylate; Bizeresin; Bleomycin sulfate; Buquina sodium; Bropiridamine; Busulfan; Actinomycin C; Carotene; Caracetamide; Carbetim; Carboplatin; Carmustine; Carrubicin hydrochloride; Carzeresin; Cedifenol; Chlorambucil; Ciromycin; Cisplatin; Cladribine; Crestor mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Actinomycin D; Daunorubicin hydrochloride decitabine; dextromaplatin; dezaguanine; dezaguanine mesylate; diazurone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; drolostanone propionate; dazomicin; edatrexamate; eflornithine hydrochloride; elsamitrucin; enloplatin; enprobamate; epipipridine; epirubicin hydrochloride; erbulazole; esorubicin hydrochloride; estramustine; estramustine sodium phosphate; etanidazole; etoposide; etoposide phosphate floxacin; etobranin; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flucitabine; fosquatone; fostramoxine sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; imofosine; interleukin II (including recombinant interleukin II or rIL2); interferon α-2a; interferon α-2b; interferon α-n1; interferon α-n3; interferon β-I a; interferon gamma-Ib; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; lirazol hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprofen; maytansine; nitrogen mustard hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menolipir; mercaptopurine; methotrexate; methotrexate sodium; chlorpheniramine; metodepa; mibutidamide; mitocarcin; mitocromin; mitocrinol; mitomycin; mitosperm; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nortriptyline codazole; nogamycin; ormaplatin; oxysulam; paclitaxel; pegaspargase; pelimycin; pentamidine; pelimycin sulfate; perfosfamide; piperobroman; piperosulfan; pyroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazolidinone; liboadenosine; roglulimide; safingol; safingol hydrochloride; semustine; sphenobarbital; spardronate sodium; sparmycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptozotocin; streptozotocin; sulfochlorophenylurea; talithromycin; tecogalan sodium; tegafur;Tiloxantrone hydrochloride; temoporfin; teniposide; tiloxilon; testolactone; thiamidoprine; thioguanine; thiotepa; thiazolamide nucleoside; tirapazamine; toremifene citrate; triptolon acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronide; triptorelin; tobradazole hydrochloride; uramustine; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinpitidine sulfate; vinca glyceride sulfate; vinrosin sulfate; vinorelbine tartrate; vinprodine sulfate; vinblastine sulfate; vorozole; zeniplatin; ningastatin; zorubicin hydrochloride. Other examples of anticancer drugs include, but are not limited to, 20-epi-1,25-dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adenosine; adolesin; aldesleukin; ALL-TK antagonists; hexamethylmelamine; aminomustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; anrelix; anti-dorsalizing morphogenetic protein-1 (anti-dorsalizing morphogenetic protein-1); protein-1); antiandrogen; prostate cancer; antiestrogens; antineoplastons; antisense oligonucleotides; glycine aphidicolin; apoptosis gene regulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; amustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; diazotyrosine; baccatin III derivatives; balanol; batimastat; BCR / ABL antagonists; benzochlorins; benzoylstaurosporine; β-lactam derivatives; β-alethine; betaclamycin B; betulinic acid; bFGF inhibitors; bicalutamide; bisantrene; diaziridinylspermine; binefad; bistratene A A); biszelesin; breflate; bropiridamine; budotetan; buthionine sulfate imide; calcipotriol; calciphosphotin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamide triazole; CaRest M3; CARN 700; cartilage-derived inhibitor; caszelesin; casein kinase inhibitor (ICOS); castanospermine; cecropin B; cetrorelix; chlorin; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomiphene analogs; clotrimazole; collismycin A; collismycin B; conpratin A4; conpratin analogs; conagenin;crambescidin816; crestol; candidin 8; candidin A derivative; curacin A; cyclopentanthrone; cycloplatam; cepimycin; cytarabine octadecyl phosphate; cytolytic factor; estradiol phosphate (cytostatin); dacilizumab; decitabine; dehydrocannabinol B; deslorelin; dexamethasone; right ifosfamide; dexrazoxane; right verapamil; diazocone; candidin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dihydrotaxol; dioxamycin ; diphenylspiromustine; docetaxel; docosyl alcohol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edilfosine; edrecolomab; eflornithine; elemene; ethiprofen; epirubicin; aprelet; estramustine analogs; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; fulamivir Pingdu; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; fomemax; formestane; fostramoxine; fomastine; gadoliniumtexaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylenebisacetamide; gold sildenafil; ibandronic acid; idarubicin; idoxifene; idarubicin ... F); triacetate spirochetin-N; lanreotide; ranamycin; levograstim; lentinan sulfate; rebostatin; letrozole; leukemia inhibitory factor; interferon alpha; leuprolide + estrogen + progesterone; leuprolide; levamisole; lirazole; linear polyamine analogs; lipophilic disaccharide peptides; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; earthworm phospholipids; lometrexol; lonidamine; losoxantrone; HMG-CoA reductase inhibitors (such as but not limited to lovastatin, pravastatin, fluvastatin, statins, simvastatin and atorvastatin); loxoribine; lutetium texaphyrin; lysofylline; lytic peptide; maytansine; manostatin A; marimastat; masoprofol; mammostatin;matrix lytic factor inhibitor; matrix metalloproteinase inhibitor; menolipir; merbarone; avorelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; miriproxyprogesterone; mismatched double-stranded RNA; mitoxantrone; dibromodole; mitomycin analog; mitonadamide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofaradine; morasporoxyprogesterone; human chorionic gonadotropin monoclonal antibody; monophosphoryl lipid A+ mycobacterial cell wall sk; mopidarol; multidrug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; Indian Ocean sponge B (mycaperoxide B); mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone + pentazocine; napavin; naphterpin; narostem; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidants; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducers; ormaplatin; osetaxelone; oxadiazine oxaunomycin; paclitaxel; paclitaxel analogs; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronate; panaxatriol; panomifen; parabactin; pozeptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; pyrexine; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compound; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl diacridone; prostaglandin J2; proteasome inhibitor; protein A-based immunomodulator; protein kinase C inhibitor; protein kinase C inhibitor; microalgae; protein tyrosine phosphatase inhibitor; purine nucleoside phosphorylase inhibitor; purpurin; methoxypyrazoline acridine; pyridoxal hemoglobin polyoxyethylene conjugate; raf antagonist; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitor; ras inhibitor; ras-GAP inhibitor; demethylated retiptine; rhenium Re 186 etidronate; rhizoxin; ribozyme; RII isotretinoin; roglulimide; roxitomine; romotide; roquimek; rubiginone B1; ruboxyl; safinol; saintopin;SarCNU; myophytol A; sargramostim; Sdi 1 mimetic; semustine; senescence-derived inhibitor 1; sense oligonucleotide; signal transduction inhibitor; signal transduction regulator; single-chain antigen binding protein; sizoran; sobuzosine; borcarbazine sodium; sodium phenylacetate; solverol; somatomedin binding protein; sonarmin; fospartate; spicamycin D; spiromustine; spongistatin 1 1); squalamine; stem cell inhibitor; stem cell division inhibitor; stipiamide; stromelysin inhibitor; sulfinosine; potent vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycan; tamustine; tamoxifen methylthiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitor; temoporfin; temozolomide; teniposide; tetrachlorodecaoxid; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymofasin; thymopoietin receptor agonist; thymosin; thyroid stimulating hormone; tin ethyletiopurpurin; tirapazamine; titanocene dichloride bichloride); topsentin; toremifene; totipotent stem cell factor; translation inhibitor; retinoic acid; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turotelene; tyrosine kinase inhibitor; tyrosine phosphorylation inhibitor (tyrphostin); UBC inhibitor; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonist; vapreotide; variolin B; vector system; erythrocyte gene therapy; vilaresol; veratramine; verdins; verteporfin; vinorelbine; vinxaltine; Vorozole; zanotron; zeniplatin; zilascorb; and zestatin. Other anticancer drugs are 5-fluorouracil and folinic acid. These two agents are particularly useful when used in a method using thalidomide and a topoisomerase inhibitor. In some embodiments, the anti-BCMA targeting trispecific proteins of the present disclosure are used in combination with gemcitabine.

[0239] In some embodiments, the anti-BCMA targeting trispecific proteins described herein are administered before, during, or after surgery.

[0240] In some embodiments, the anticancer agent is conjugated to the trispecific protein by any suitable means.

[0241] Detection of BCMA expression and diagnosis of BCMA-related cancers

[0242] According to another embodiment of the present disclosure, a kit for detecting BCMA expression in vitro and / or in vivo is provided. The kit includes the aforementioned BCMA-targeted trispecific protein (e.g., a trispecific protein containing a labeled anti-BCMA single domain antibody or an antigen-binding fragment thereof), and one or more compounds for detecting markers. In some embodiments, the marker is selected from a fluorescent marker, an enzyme marker, a radioactive marker, a nuclear magnetic resonance active marker, a luminescent marker, and a chromophore marker.

[0243] In some cases, BCMA expression is detected in a biological sample. The sample can be any sample, including but not limited to tissues from biopsies, autopsies, and pathological specimens. Biological samples also include tissue sections, for example, frozen sections for histological purposes. Biological samples also include body fluids, such as blood, serum, plasma, sputum, cerebrospinal fluid, or urine. Biological samples are typically obtained from mammals, such as humans or non-human primates.

[0244] Samples obtained for use in the assays described herein include tissues and body fluids, and can be processed using conventional means in the art (e.g., homogenization, serum separation, etc.). Therefore, prior to use in the assays described herein, samples obtained from patients are converted. If BCMA is present in the sample, BCMA is further converted by binding to, for example, an antibody in the manner described herein.

[0245] In one embodiment, a method for determining whether a subject has cancer is provided by contacting a sample from the subject with an anti-BCMA single domain antibody disclosed herein and detecting binding of the single domain antibody to the sample. An increase in binding of the antibody to the sample compared to binding of the antibody to a control sample determines that the subject has cancer.

[0246] In another embodiment, a method for confirming the diagnosis of cancer in a subject is provided by contacting a sample from a subject diagnosed with cancer with an anti-BCMA single domain antibody disclosed herein and detecting binding of the antibody to the sample. Increased binding of the antibody to the sample as compared to binding of the antibody to a control sample confirms the diagnosis of cancer in the subject.

[0247] In some examples of the disclosed methods, the BCMA single domain antibody or trispecific protein is directly labeled.

[0248] In some examples, the method further comprises contacting the sample with a second antibody that specifically binds to the anti-BCMA single domain antibody; and detecting binding of the second antibody. Increased binding of the second antibody to the sample as compared to binding of the second antibody to a control sample detects cancer in the subject or confirms a diagnosis of cancer in the subject.

[0249] In some instances, the cancer is leukemia, lymphoma, multiple myeloma, or any other type of cancer that expresses BCMA.

[0250] In some instances, the control sample is a sample from a subject without cancer. In specific instances, the sample is a blood or tissue sample.

[0251] In some cases, the antibody that binds (e.g., specifically binds) BCMA is directly labeled with a detectable marker. In another embodiment, the antibody (first antibody) that binds (e.g., specifically binds) BCMA is not labeled, and the second antibody or other molecules that can bind to the antibody that specifically binds BCMA are labeled. The second antibody is selected so that it can specifically bind to the first antibody of a specific species and class. For example, if the first antibody is llama IgG, the second antibody can be anti-llama IgG. Other molecules that can be bound to the antibody include, but are not limited to, protein A and protein G, both of which are commercially available. Suitable markers for antibodies or second antibodies are as described above, and include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, magnetic agents, and radioactive materials. Non-limiting examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase. Non-limiting examples of suitable prosthetic group complexes include streptavidin / biotin and avidin / biotin. Non-limiting examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin. A non-limiting exemplary luminescent material is luminol; a non-limiting exemplary magnetic agent is gadolinium, and non-limiting exemplary radioactive labels include 125I, 131I, 35S or 3H.

[0252] In an alternative embodiment, BCMA can be measured in a biological sample by a competitive immunoassay that uses a BCMA standard labeled with a detectable substance and an unlabeled antibody that specifically binds to BCMA. In this assay, the biological sample, the labeled BCMA standard, and the antibody that specifically binds to BCMA are mixed together, and the amount of the labeled BCMA standard bound to the unlabeled antibody is measured. The amount of BCMA in the biological sample is inversely proportional to the amount of the labeled BCMA standard bound to the antibody that specifically binds to BCMA.

[0253] The immunoassays and methods disclosed herein can be used for a variety of purposes. In one embodiment, an antibody that specifically binds to BCMA can be used to detect the production of BCMA in cells in cell culture. In another embodiment, the antibody can be used to detect the amount of BCMA in a biological sample such as a tissue sample or a blood or serum sample. In some instances, the BCMA is cell surface BCMA. In other instances, the BCMA is soluble BCMA (e.g., BCMA in a cell culture supernatant or a soluble BCMA in a body fluid sample such as a blood or serum sample.

[0254] In one embodiment, a kit for detecting BCMA in a biological sample such as a blood sample or a tissue sample is provided. For example, in order to confirm a cancer diagnosis in a subject, a biopsy can be performed to obtain a tissue sample for histological examination. Alternatively, a blood sample can be obtained to detect the presence of a soluble BCMA protein or fragment. According to the present disclosure, a kit for detecting a polypeptide will generally include a single domain antibody that specifically binds to BCMA. In some embodiments, an antibody fragment, such as an scFv fragment, a VH domain, or a Fab is included in the kit. In a further embodiment, the antibody is labeled (e.g., labeled with a fluorescent, radioactive, or enzyme marker).

[0255] In one embodiment, the kit includes explanatory materials that disclose means for using antibodies that bind BCMA. The explanatory materials may be written, electronic (such as a computer floppy disk or CD), or visual (such as a video file), or provided via an electronic network, such as the Internet, the World Wide Web, an intranet, or other networks. The kit may also include other components to facilitate the specific application for which the kit is designed. Thus, for example, the kit may additionally include means for detecting the marker (such as an enzyme substrate for an enzyme marker, a filter kit for detecting a fluorescent marker, a suitable second marker, such as a second antibody, etc.). The kit may additionally include buffers and other reagents conventionally used to implement a particular method. Such kits and suitable contents are well known to those skilled in the art.

[0256] In one embodiment, the diagnostic kit includes an immunoassay. Although the details of the immunoassay may vary depending on the particular format employed, the method of detecting BCMA in a biological sample generally includes the step of contacting the biological sample with an antibody that specifically reacts with a BCMA polypeptide under immunoreactive conditions. The antibody is allowed to specifically bind under immunoreactive conditions to form an immune complex, and the presence of the immune complex (bound antibody) is detected directly or indirectly.

[0257] Methods for determining the presence or absence of cell surface markers are well known in the art. For example, antibodies can be conjugated to other compounds including but not limited to enzymes, magnetic beads, colloidal magnetic beads, haptens, fluorescent dyes, metal compounds, radioactive compounds or drugs. Antibodies can also be used in immunoassays, such as but not limited to radioimmunoassays (RIA), ELISA or immunohistochemistry assays. Antibodies can also be used in fluorescence-activated cell sorting (FACS). FACS uses multiple color channels, low-angle and obtuse light scattering detection channels, and impedance channels, as well as other more complex detection levels, to separate or classify cells (see U.S. Pat. No. 5,061,620). As disclosed herein, any single domain antibody that binds BCMA can be used in these assays. Therefore, these antibodies can be used in conventional immunoassays, including but not limited to ELISA, RIA, FACS, tissue immunohistochemistry, Western blotting or immunoprecipitation.

[0258] The present invention provides embodiments including but not limited to the following:

[0259] 1. A B cell maturation agent (BCMA) binding trispecific protein comprising:

[0260] (a) the first domain (A) that specifically binds to human CD3;

[0261] (b) a second domain (B) which is a half-life extension domain; and

[0262] (c) the third domain (C) that specifically binds to BCMA,

[0263] The domains are connected in the order of H2N-(A)-(C)-(B)-COOH, H2N-(B)-(A)-(C)-COOH, H2N-(C)-(B)-(A)-COOH, H2N-(C)-(A)-(B)-COOH, H2N-(A)-(B)-COOH, H2N-(A)-(B)-(C)-COOH or H2N-(B)-(C)-(A)-COOH, wherein the domains are connected by linkers L1 and L2.

[0264] 2. The BCMA-binding trispecific protein of claim 1, wherein the first domain comprises a variable light chain domain and a variable heavy chain domain, each of which is capable of specifically binding to human CD3.

[0265] 3. The BCMA-binding protein of claim 1, wherein the first domain is humanized or human.

[0266] 4. The BCMA-binding trispecific protein of claim 1, wherein the second domain binds to albumin.

[0267] 5. The BCMA-binding trispecific protein of claim 1, wherein the second domain comprises a scFv, a variable heavy chain domain (VH), a variable light chain domain (VL), a VHH domain, a peptide, a ligand, or a small molecule.

[0268] 6. The BCMA-binding trispecific protein of claim 1, wherein the third domain comprises a VHH domain, a scFv, a VH domain, a VL domain, a non-Ig domain, a ligand, a knottin, or a small molecule entity that specifically binds to BCMA.

[0269] 7. The BCMA-binding trispecific protein of claim 6, wherein the third domain comprises a VHH domain.

[0270] 8. The BCMA-binding trispecific protein of claim 7, wherein the VHH domain comprises complementarity determining regions CDR1, CDR2 and CDR3, wherein

[0271] (a) The amino acid sequence of CDR1 is X1X2X3X4X5X6X7PX8G (SEQ ID NO:

[0272] 1) is shown, wherein X1 is T or S; X2 is N, D or S; X3 is I, D, Q, H, V or E; X4 is F, S, E, A, T, M, V, I, D, Q, P, R or G; X5 is S, M, R or N; X6 is I, K, S, T, R, E, D, N, V, H, L, A, Q or G; X7 is S, T, Y, R or N; and X8 is M, G or Y;

[0273] (b) The amino acid sequence of CDR2 is AIX9GX 10 X 11 TX 12 YADSVK (SEQ ID

[0274] NO:2) shows that X9 is H, N or S; X 10 is F, G, K, R, P, D, Q, H, E, N, T, S, A, I, L, or V; X 11 is S, Q, E, T, K or D;

[0275] And X 12 is L, V, I, F, Y or W; and

[0276] (c) The amino acid sequence of CDR3 is VPWGX 13 YXX 14 X 15 VX 16 (SEQ ID NO:

[0277] 3) shows that X 13 is D, I, T, K, R, A, E, S or Y; X 14 R, G, L, K, T, Q, S or N; X 15 is N, K, E, V, R, M or D; and

[0278] X 16 is Y, A, V, K, H, L, M, T, R, Q, C, S or N; and wherein CDR1 is not SEQ ID NO:599, wherein CDR2 is not SEQ ID NO:600, and wherein CDR3 is not SEQ ID NO:601.

[0279] 9. The BCMA-binding trispecific protein of claim 8, wherein the VHH domain comprises the formula:

[0280] f1-r1-f2-r2-f3-r3-f4

[0281] wherein r1 is SEQ ID NO:1; r2 is SEQ ID NO:2; and r3 is SEQ ID NO:3; and wherein f1, f2, f3 and f4 are selected framework residues such that the protein is about eighty percent (80%) to about 99% identical to the amino acid sequence shown in SEQ ID NO:346 or 598.

[0282] 10. The BCMA-binding trispecific protein of claim 9, wherein r1 comprises the amino acid sequence shown in any one of SEQ ID NOs: 4-117.

[0283] 11. The BCMA-binding trispecific protein of claim 9, wherein r2 comprises the amino acid sequence shown in any one of SEQ ID NOs: 118-231.

[0284] 12. The BCMA-binding trispecific protein of claim 9, wherein r3 comprises the amino acid sequence shown in any one of SEQ ID NOs: 232-345.

[0285] 13. The BCMA-binding trispecific protein of claim 9, wherein the VHH domain comprises the amino acid sequence shown in any one of SEQ ID NOs: 346-460.

[0286] 14. The BCMA-binding trispecific protein of claim 9, wherein F1 comprises SEQ ID NO: 461 or 462.

[0287] 15. The BCMA-binding trispecific protein of claim 9, wherein F2 comprises SEQ ID NO: 463.

[0288] 16. The BCMA-binding trispecific protein of claim 9, wherein F3 comprises SEQ ID NO: 464 or 465.

[0289] 17. The BCMA-binding trispecific protein of claim 9, wherein F4 comprises SEQ ID NO: 466 or 467.

[0290] 18. The BCMA-binding trispecific protein of claim 9, wherein r1 comprises SEQ ID NO: 76, 114, 115, 116 or 117.

[0291] 19. The BCMA-binding trispecific protein of claim 9, wherein r1 comprises SEQ ID NO:76, r2 is SEQ ID NO:190, and r3 is SEQ ID NO:304.

[0292] 20. The BCMA-binding trispecific protein of claim 9, wherein r1 comprises SEQ ID NO: 114, r2 comprises SEQ ID NO: 228, and r3 comprises SEQ ID NO: 342.

[0293] 21. The BCMA-binding trispecific protein of claim 9, wherein r1 comprises SEQ ID NO: 115, r2 comprises SEQ ID NO: 229, and r3 comprises SEQ ID NO: 343.

[0294] 22. The BCMA-binding trispecific protein of claim 9, wherein r1 comprises SEQ ID NO: 117, r2 comprises SEQ ID NO: 231, and r3 comprises SEQ ID NO: 345.

[0295] 23. The BCMA-binding trispecific protein of claim 9, wherein r1 comprises SEQ ID NO: 116, r2 comprises SEQ ID NO: 230, and r3 comprises SEQ ID NO: 344.

[0296] 24. The BCMA-binding trispecific protein of any one of claims 1-23, wherein the third domain is a human VHH domain, a humanized VHH domain, an affinity matured VHH domain, or a combination thereof.

[0297] 25. The BCMA-binding tri-specific protein of any one of claims 1-24, wherein the protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

[0298] 26. The BCMA-binding trispecific protein of claim 7, wherein the VHH domain comprises CDR1, CDR2, and CDR3, and wherein the protein comprises the sequence shown in SEQ ID NO: 598 or 346, wherein one or more amino acid residues selected from amino acid positions 26, 27, 28, 29, 30, 31, 32, and 34 of CDR1, positions 52, 54, 55, and 57 of CDR2, and positions 101, 105, 106, and 108 of CDR3 are substituted, wherein

[0299] Amino acid position 26, if substituted, is substituted with S;

[0300] Amino acid position 27, if substituted, is substituted with D or S;

[0301] Amino acid position 28, if substituted, is substituted with D, Q, H, V, or E;

[0302] amino acid position 29, if substituted, is substituted with S, E, A, T, M, T, V, I, D, Q, D, P, R, or G;

[0303] Amino acid position 30, if substituted, is substituted with M, R, or N;

[0304] amino acid position 31, if substituted, is substituted with K, S, T, R, E, D, N, V, H, L, A, Q, or G;

[0305] Amino acid position 32, if substituted, is substituted with T, Y, R, or N;

[0306] Amino acid position 34, if substituted, is substituted with G or Y;

[0307] Amino acid position 52, if substituted, is substituted with N or S;

[0308] amino acid position 54, if substituted, is substituted with G, K, R, P, D, Q, H, E, N, T, S, A, I, L, or V;

[0309] Amino acid position 55, if substituted, is substituted with Q, E, T, K, or D;

[0310] Amino acid position 57, if substituted, is substituted with V, I, F, Y, or W;

[0311] Amino acid position 101, if substituted, is substituted with I, T, K, R, A, E, S, or Y;

[0312] Amino acid position 105, if substituted, is substituted with G, L, K, T, Q, S, or N;

[0313] Amino acid position 106, if substituted, is substituted with K, E, V, R, M, or D;

[0314] If amino acid position 108 is substituted, it is substituted with A, V, K, H, L, M, T, R, Q, C, S or N.

[0315] 27. The BCMA-binding trispecific protein of claim 26, wherein the VHH domain is human, humanized, affinity matured, or a combination thereof.

[0316] 28. The BCMA-binding tri-specific protein of any one of claims 1-27, wherein the third domain binds to a human BCMA protein comprising the sequence shown in SEQ ID NO: 468.

[0317] 29. The BCMA-binding tri-specific protein of any one of claims 1-27, wherein the third domain binds to the extracellular domain of BCMA.

[0318] 30. The BCMA-binding trispecific protein of any one of claims 1-29, wherein linkers L1 and L2 are each independently selected from (GS) n (SEQ ID NO:472), (GGS) n (SEQ ID NO:473), (GGGS) n (SEQ ID NO:474), (GGSG) n (SEQ ID NO:475), (GGSGG) n (SEQ ID NO:476), (GGGGS) n (SEQ ID NO:477), (GGGGG) n (SEQ ID NO:478) or (GGG) n (SEQ ID NO:479), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0319] 31. The BCMA-binding trispecific protein of any one of claims 1-30, wherein linkers L1 and L2 are each independently (GGGGS)4 (SEQ ID NO: 480) or (GGGGS)3 (SEQ ID NO: 481).

[0320] 32. The BCMA-binding tri-specific protein of any one of claims 1-31, wherein the domains are linked in the order of H2N-(C)-(B)-(A)-COOH.

[0321] 33. The BCMA-binding tri-specific protein of any one of claims 1-32, wherein the protein is less than about 80 kDa.

[0322] 34. The BCMA-binding tri-specific protein of any one of claims 1-32, wherein the protein is about 50 to about 75 kDa.

[0323] 35. The BCMA-binding tri-specific protein of any one of claims 1-32, wherein the protein is less than about 60 kDa.

[0324] 36. The BCMA-binding tri-specific protein of any one of claims 1-35, wherein the protein has an elimination half-life of at least about 50 hours.

[0325] 37. The BCMA-binding tri-specific protein of any one of claims 1-36, wherein the protein has an elimination half-life of at least about 100 hours.

[0326] 38. The BCMA-binding trispecific protein of any one of claims 1-37, wherein the protein has increased tissue penetration compared to IgG for the same BCMA.

[0327] 39. The BCMA-binding tri-specific protein of any one of claims 1-38, wherein the protein comprises a sequence selected from the group consisting of SEQ ID NOs: 483-597.

[0328] 40. The BCMA-binding tri-specific protein of any one of claims 1-39, wherein the protein comprises the sequence shown in SEQ ID NO: 520.

[0329] 41. A pharmaceutical composition comprising the BCMA-binding trispecific protein according to any one of claims 1-40, and a pharmaceutically acceptable carrier.

[0330] 42. A method for producing a BCMA-binding trispecific protein according to any one of claims 1-40, the method comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the BCMA-binding trispecific protein according to any one of claims 1-40 under conditions that allow expression of the BCMA-binding trispecific protein, and recovering and purifying the produced protein from the culture.

[0331] 43. A method for treating or improving a BCMA-related tumor disease, autoimmune disease or infectious disease in a subject in need thereof, comprising administering the pharmaceutical composition of claim 41 to the subject.

[0332] 44. The method of claim 43, wherein the subject is a human.

[0333] 45. The method of claim 43 or 44, wherein the method further comprises administering one or more additional agents in conjunction with the BCMA-binding trispecific protein.

[0334] 46. ​​The method of any one of claims 43-45, comprising treating or ameliorating a neoplastic disease, wherein the BCMA-binding trispecific protein selectively binds to tumor cells expressing BCMA.

[0335] 47. The method according to any one of claims 43-46, comprising treating or ameliorating a neoplastic disease, wherein the neoplastic disease comprises a primary cancer or a metastasis thereof.

[0336] 48. The method of claim 47, wherein the neoplastic disease comprises a B-cell lineage cancer.

[0337] 49. The method of claim 48, wherein the B-cell lineage cancer is multiple myeloma, leukemia, lymphoma, or a metastasis thereof.

[0338] 50. A B cell maturation agent (BCMA) binding trispecific protein comprising:

[0339] (a) the first domain (A) that specifically binds to human CD3;

[0340] (b) a second domain (B) which is a half-life extension domain; and

[0341] (c) the third domain (C) that specifically binds to BCMA,

[0342] Wherein the third domain comprises the amino acid sequence shown in any one of SEQ ID NOs: 346-460.

[0343] 51. A B cell maturation agent (BCMA) binding trispecific protein comprising:

[0344] (a) the first domain (A) that specifically binds to human CD3;

[0345] (b) a second domain (B) which is a half-life extension domain; and

[0346] (c) the third domain (C) that specifically binds to BCMA,

[0347] The third domain comprises CDR1, CDR2 and CDR3, wherein CDR1 comprises the amino acid sequence shown in any one of SEQ ID NOs: 4-117, CDR2 comprises the amino acid sequence shown in any one of SEQ ID NOs: 118-231, and CDR3 comprises the amino acid sequence shown in any one of SEQ ID NOs: 232-345.

[0348] 52. A method for treating or ameliorating a BCMA-related neoplastic disease, autoimmune disease or infectious disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a BCMA-binding trispecific protein, wherein the BCMA-binding protein comprises

[0349] (a) the first domain (A) that specifically binds to human CD3;

[0350] (b) a second domain (B) which is a half-life extension domain; and

[0351] (c) the third domain (C) that specifically binds to BCMA,

[0352] The domains are H2N-(A)-(C)-(B)-COOH, H2N-(B)-(A)-(C)-

[0353] COOH, H2N-(C)-(B)-(A)-COOH, H2N-(C)-(A)-(B)-COOH, H2N-

[0354] The domains are connected sequentially by (A)-(B)-(C)-COOH, H2N-(B)-(C)-(A)-COOH, wherein the domains are connected by linkers L1 and L2.

[0355] Example

[0356] The present application may be better understood by reference to the following non-limiting examples provided as exemplary embodiments of the present application. The following examples are presented to more fully illustrate the embodiments, but should in no way be construed as limiting the broad scope of the present application.

[0357] Example 1

[0358] Protein production

[0359] The sequence of the BCMA-targeted trispecific molecule containing the BCMA-binding protein according to the present disclosure was cloned into the mammalian expression vector pcDNA 3.4 (Invitrogen), which was preceded by a leader sequence and followed by a 6x histidine tag (SEQ ID NO: 471). Expi293 cells (Life Technologies A14527) were suspended in Expi293 medium in Optimum Growth Flasks (Thomson) at 0.2-8×1e6 cells / mL. Purified plasmid DNA was transfected into Expi293 cells according to the Expi293 Expression System Kit (Life Technologies, A14635) protocol and maintained for 4-6 days after transfection. In the conditioned medium, an Octet instrument with a protein A tip was used, and a standard curve was made using a control trispecific protein to quantify the amount of the measured exemplary trispecific protein from the transfected Expi293 cells in the conditioned medium.

[0360] T cell-dependent cytotoxicity assay

[0361] Titration of conditioned medium was added to the TDCC assay (T cell dependent cytotoxicity assay) to evaluate whether the anti-BCMA single domain antibody can form synapses between T cells and BCMA expressing cell lines and guide T cells to kill BCMA expressing cell lines. In this assay (Nazarian et al., 2015. J. Biomol. Screen., 20:519-27), T cells and target cancer cell line cells are mixed together in a 10:1 ratio in a 384-well plate and different amounts of the tested trispecific proteins are added. Tumor cell lines were engineered to express luciferase protein. After 48 hours, in order to quantify the remaining viable tumor cells, the luciferase protein was added using Luminescent Assay (Promega).

[0362] In this example, EJM cells were used, which are a cell line that serves as an in vitro model of multiple myeloma and plasma cell leukemia. The viability of the EJM cells was measured after 48 hours. It can be seen that the trispecific protein mediated T cell killing. Figure 2Example cell viability assays performed with test proteins 01H08, 01F07, 02F02, and BH253 compared to negative controls are shown. Table 1 below lists the EC values ​​for TDCC activity of several other trispecific proteins tested. 50 .

[0363] Binding affinity

[0364] In this study, the binding affinity of BCMA-targeted trispecific proteins containing BCMA-binding proteins according to the present disclosure to human BCMA protein was determined. The affinity measurement results are listed in Table 1.

[0365] Table 1: Binding affinity and TDCC activity of several BCMA-targeting trispecific proteins.

[0366]

[0367]

[0368]

[0369]

[0370] ND: Not determined.

[0371] Compared to the molecule 253BH10 with the parent CDRs, the molecules 01H08, 01F07, 01H06, 02G02, 02B05, 01C01, 02F02, 02E05, 01E08, 02C01, 02E06, 02B06, 02F04, 01G08, 02C06, 01H09, 01F04, 01D02, 02D11, 01A07, 02C03, 02F07, 01E04, 02H09, 01E03, 02F05, 01B05, 01C05, 02F12, 01H11, 02G06, 01E06, 01G11, 02A05, 01A08 , 02G05, 01B09, 01G01, 01B06, 01F10, 01E05, 02G01, 01A06, 02B04, 01D06, 02B07, 02B11, 01H04, 01D03, 01A05, 02F11, 01D04, 01B04, 02C05, 02E03, 01D05, 01C04, 01E07, 01G06, 02F06, 01B01, 01D07, 02A08, 01A02, 02G11, 01G04, 02F03, 01C06, 01A01 had at least a two-fold increase in TDCC potency and also showed increased affinity.

[0372] Compared with the molecule 253BH10 with the parent CDR, the molecules 01H08, 01F07, 01H06, 02G02, 02B05, 01C01, 02F02, 02E05, 01E08, 02C01, 02E06, 02B06, 02F04, 01G08, 02C06, 01H09, 01F04, 01D02, 02D11 , 01A07, 02C03, 02F07, 01E04, 02H09, 01E03, 02F05, 01B05, 01C05, 02F12, 01H11, 02G06, 01E06, 01G11, 02A05, 01A08, 02G05, and 01B09 had at least a ten-fold increase in TDCC potency and also showed increased affinity.

[0373] An anti-GFP trispecific molecule included in these assays as a negative control had no detectable BCMA binding in the TDCC assay and had no effect on cell viability (data not shown).

[0374] Example 2

[0375] Evaluation of the exemplary BCMA-targeting trispecific proteins according to the present disclosure for Jeko1,

[0376] Methods of binding and cytotoxic activity of MOLP8 and OPM2 cells

[0377] Protein production

[0378] The sequence of the BCMA-targeted trispecific molecule containing the BCMA-binding protein according to the present disclosure was expressed using previously described vectors and methods (Running Deer and Allison, 2004. Biotechnol Prog. 20: 880-9), except that cell transfection used lipid-based reagents and nonlinearized plasmid DNA, preceded by a leader sequence and followed by a 6x histidine tag (SEQ ID NO: 471). The recombinant trispecific protein was purified using affinity chromatography, ion exchange and / or size exclusion chromatography. The purified protein was quantified using theoretical extinction coefficients and absorption spectroscopy. The image of the Coomassie-stained SDS-PAGE shows the purity of the protein ( Figure 3 ).

[0379] Cytotoxicity assay

[0380] The ability of T cell engagers (including trispecific molecules) to direct T cells to kill tumor cells was measured using the human T cell-dependent cytotoxicity (TDCC) assay (Nazarian et al., 2015. J Biomol Screen. 20:519-27). In this assay, T cells and target cancer cell line cells were mixed together in a 10:1 ratio in a 384-well plate and different amounts of the tested trispecific proteins were added. The tumor cell line was engineered to express the luciferase protein. After 48 hours, in order to quantify the remaining viable tumor cells, the luciferase protein was added using Luminescent Assay (Promega).

[0381] In this study, titrations of purified protein were added to the TDCC assay (T cell-dependent cytotoxicity assay) to assess whether anti-BCMA single domain antibodies are able to form synapses between T cells and BCMA-expressing Jeko1, MOLP8, and OPM2 cancer cell lines. Jeko1 is a B cell lymphoma cell line. MOLP-8 is a myeloma cell line. OPM-2 is a human myeloma cell line.

[0382] The viability of the cells was measured after 48 hours. It can be seen that the trispecific protein mediated T cell killing. Figure 4 shows an example cell viability assay performed with the test protein compared to a negative control. Table 2 below lists the EC values ​​for TDCC activity of several other trispecific proteins tested. 50 An anti-GFP trispecific molecule, included in these assays as a negative control, had no effect on cell viability (data not shown).

[0383] Table 2: TDCC ECs of selected BCMA-targeting trispecific proteins in the TriTAC format (anti-target (BCMA): anti-albumin: anti-CD3 binding domain) against 3 cell lines 50 value.

[0384]

[0385] Binding affinity

[0386] In the present study, the binding affinity of BCMA-targeting trispecific proteins containing the BCMA-binding protein according to the present disclosure to human BCMA protein was determined.

[0387] Table 3: Binding affinities of purified targeted trispecific proteins containing BCMA binding proteins according to the present disclosure

[0388]

[0389] Figure 3The data in Figure 4, Table 2 and Table 3 show that the BCMA-targeted trispecific protein can be expressed and purified to a purity greater than 90%. The purified protein exhibits about 13- to 213-fold more potent TDCC activity than the trispecific protein with the parent BCMA targeting sequence. The purified trispecific protein binds to BCMA with an affinity of about 3 to 7 nM.

[0390] Example 3

[0391] Xenograft tumor models

[0392] The exemplary BCMA-targeting trispecific proteins described herein were evaluated in a xenograft model.

[0393] On day 0, NCG mice were subcutaneously inoculated with RPMI-8226 cells and additionally implanted intraperitoneally with normal human peripheral blood mononuclear cells (PBMCs). Treatment with an exemplary BCMA-targeted trispecific protein (02B05) (SEQ ID NO: 520) also began on day 0 (qdx10) (once a day for 10 days). The doses administered were 5 μg / kg, 50 μg / kg, or 500 μg / kg of the BCMA-targeted trispecific protein 02B05, or vehicle as a control. Tumor volume was measured for 25 days. Fig.30 As shown, the mean tumor volume was significantly lower in mice treated with an exemplary BCMA-targeting tri-specific protein (02B05) (50 μg / kg or 500 μg / kg) compared to mice treated with vehicle or a lower dose of the BCMA-targeting tri-specific protein (02B05) (5 μg / kg).

[0394] On day 0, NCG mice were subcutaneously inoculated with Jeko 1 cells and additionally implanted with normal human peripheral blood mononuclear cells (PBMCs) intraperitoneally. Treatment with an exemplary BCMA-targeted trispecific protein (02B05) (SEQ ID NO: 520) was initiated on day 3 (qdx10) (once a day for 10 days). Doses were 5 μg / kg, 50 μg / kg, or 500 μg / kg of BCMA-targeted trispecific protein 02B05, or vehicle as a control. Tumor volume was measured for 25 days. Fig.31 As shown, the mean tumor volume was significantly lower in mice treated with an exemplary BCMA-targeting tri-specific protein (02B05) (500 μg / kg) compared to mice treated with vehicle or a lower dose of the BCMA-targeting tri-specific protein (02B05) (5 μg / kg or 50 μg / kg).

[0395] Example 4

[0396] Proof-of-concept clinical trial protocol for administering the BCMA trispecific antigen binding proteins of the present disclosure to multiple myeloma patients

[0397] This is a Phase I / II clinical trial for studying the BCMA trispecific antigen binding protein of Example 1 as a treatment for multiple myeloma.

[0398] Research findings:

[0399] Primary: Maximum tolerated dose of the BCMA-targeted trispecific protein of the aforementioned example Secondary: Determine whether the in vitro response of the BCMA-targeted trispecific protein of the aforementioned example is correlated with clinical response

[0400] Phase I

[0401] The maximum tolerated dose (MTD) was determined in the Phase I portion of the trial.

[0402] 1.1 The maximum tolerated dose (MTD) was determined in the Phase I part of this trial.

[0403] 1.2 Patients meeting the eligibility criteria are enrolled in the trial for the BCMA-targeting trispecific protein of the aforementioned example.

[0404] 1.3 The goal is to determine the highest dose at which the BCMA-targeted trispecific protein of the aforementioned example can be safely administered to participants without severe or difficult-to-handle side effects. The given dose depends on the number of participants who have previously been enrolled in the study and the degree of dose tolerance. Not all participants receive the same dose.

[0405] Phase II

[0406] 2.1 The subsequent Phase II portion was treated at the MTD with the goal of determining whether therapy using the BCMA-targeted tri-specific protein of the aforementioned example would result in a response rate of at least 20%.

[0407] The primary outcome of Phase II is to determine whether the BCMA-targeted tri-specific protein therapy using the aforementioned examples will result in at least 20% of patients achieving a clinical response (blast response, minor response, partial response, or complete response).

[0408] Eligibility

[0409] The eligibility criteria for inclusion in this study were as follows:

[0410] Patients with previously untreated multiple myeloma without severe or imminent complications (e.g., impending pathological fracture, hypercalcemia, renal insufficiency). All asymptomatic patients with low or intermediate tumor mass are eligible.

[0411] Patients with large tumors, symptomatic or impending fractures, hypercalcemia (corrected calcium >11.5 mg%), anemia (Hgb <8.5 gm / dl), renal failure (creatinine >2.0 mg / dl), high serum lactate dehydrogenase (>300 U / L), or plasma cell leukemia (>1000 / ul) were not eligible.

[0412] Obvious infection or unexplained fever should be resolved before treatment. Adequate liver function (including SGPT, bilirubin, and LDH) is required.

[0413] Patients must have a Zubrod performance score of 1 or less.

[0414] Patients were required to provide written informed consent indicating that they understood the research nature of the study.

[0415] Life expectancy should be more than 1 year.

[0416] Patients with idiopathic monoclonal gammopathy and nonsecretory multiple myeloma are not eligible. Only patients whose prior treatment was local radiation therapy, α-IFN, or ATRA are eligible. Patients who have previously received high-dose glucocorticoids or alkylating agents are not eligible.

[0417] Example 5

[0418] Using the exemplary BCMA-targeting trispecific proteins disclosed herein, human and cynomolgus monkey BCMA, CD3ε and albumin were tested. Affinity measurement of white

[0419] The purpose of this study is to evaluate the affinity of the exemplary BCMA targeting trispecific protein (02B05) (SEQ ID NO: 520) disclosed herein to human BCMA, cynomolgus BCMA, human CD3ε, cynomolgus CD3ε, human albumin, cynomolgus albumin and mouse albumin. Affinity was measured using an Octet instrument. For these measurements, 2.5nM human BCMA-Fc, 2.5nM cynomolgus BCMA-Fc, 2.5nM human CD3ε-Fc, 2.5nM cynomolgus CD3ε-Fc, 50nM human serum albumin (HSA), 50nM cynomolgus serum albumin or 50nM mouse serum albumin were first loaded to the streptavidin tip. Subsequently, the exemplary BCMA targeting trispecific protein 02B05 was incubated with the tip, and after the association period, the tip was moved to a buffer solution to dissociate the exemplary BCMA targeting trispecific protein (02B05). Binding affinities to human and cynomolgus BCMA and CD3ε were determined in the presence of 15 mg / ml human serum albumin. The average calculated K from these studies DThe values ​​are provided in Table 4 (n indicates the number of independent measurements, n / d indicates that no binding was detected under the conditions tested). Binding to human BCMA, human CD3ε, cynomolgus CD3ε, human serum albumin, cynomolgus serum albumin, and mouse serum albumin was detected. Under the conditions tested, no binding was detected to cynomolgus BCMA.

[0420] Table 4. Measured K of exemplary BCMA-targeting trispecific protein 02B05 for protein ligands D value

[0421]

[0422] Example 6

[0423] Human T cell binding capacity of exemplary BCMA-targeting trispecific proteins disclosed herein The ability of an exemplary BCMA-targeting trispecific protein 02B05 (SEQ ID NO: 520) to bind to purified T cells was tested. Briefly, BCMA trispecific proteins or phosphate-buffered saline (PBS) were incubated with purified T cells from 4 different anonymous human donors. After washing unbound protein, T cells were incubated with an Alexa Fluor 647-conjugated antibody that recognizes the anti-albumin domain in the 02B05 BCMA trispecific antigen binding protein. The T cells were then analyzed by flow cytometry. It was observed that human T cells incubated with the 02B05 BCMA trispecific antigen binding protein had a significant shift associated with Alexa Fluor 647 staining compared to cells incubated with PBS. The results are in Figure 5A , 5B , 5C and 5D. In summary, this study demonstrated that the exemplary BCMA-targeting trispecific protein is able to bind to human T cells.

[0424] Example 7

[0425] Ability of the Exemplary BCMA-Targeting Trispecific Proteins of the Present Disclosure to Bind to Cells Expressing BCMA

[0426] The ability of an exemplary BCMA-targeting trispecific protein 02B05 (SEQ ID NO: 520) to bind to cells expressing BCMA was tested. Briefly, the 02B05 BCMA trispecific antigen binding protein was incubated with cell lines expressing BCMA (NCI-H929; EJM; RPMI-8226; OPM2) or cell lines lacking BCMA (NCI-H510A; DMS-153). The expression of BCMA RNA in these cells was determined by Fig. 6A-F The FPKM (fragments per million kilobases) values ​​listed in represent: RNA FPKM values ​​are from Cancer Cell Line Encyclopedia (Broad Institute, Cambridge, MA USA). After washing unbound proteins, cells were incubated with Alexa Fluor 647-conjugated antibodies that recognize the anti-albumin domain in the 02B05 BCMA trispecific antigen binding protein. The cells were then analyzed by flow cytometry. As a negative control, cells were incubated with a trispecific protein targeting GFP. Cells expressing BCMA RNA and incubated with the BCMA trispecific protein had a significant shift associated with Alexa Fluor 647 staining compared to cells incubated with the GFP trispecific protein (as shown in Figure 2A). Fig. 6A , 6B , 6D, and 6E). However, cells lacking BCMA RNA produced equivalent Alexa Fluor 647 staining using the BCMA trispecific protein and the GFP trispecific protein (as shown in Figure 6C and 6F ). Thus, this study demonstrates that the exemplary BCMA trispecific antigen binding protein is able to selectively bind to cells expressing BCMA.

[0427] Example 8

[0428] Ability of exemplary BCMA-targeting trispecific proteins to mediate T cell killing of BCMA-expressing cancer cells

[0429] The ability of the exemplary BCMA trispecific protein 02B05 (SEQ ID NO: 520) to direct T cells to kill BCMA-expressing cells was tested in the presence and absence of human serum albumin (HSA) using a standard TDCC assay as described in Example 1. Because the exemplary BCMA trispecific protein contains an anti-albumin domain, this experiment was performed to confirm that binding to albumin would not prevent the BCMA trispecific antigen binding protein from directing T cells to kill BCMA-expressing cells. Five BCMA-expressing cell lines were tested: EJM, Jeko, OPM2, MOLP8, and NCI-H929. Representative data for experiments with EJM cells are shown in Table 1. Figure 7It was observed that the viability of EJM cells decreased with increasing amounts of the exemplary 02B05 BCMA trispecific antigen binding protein in the presence or absence of human serum albumin (HSA), while the control GFP-targeted trispecific protein did not affect cell viability. In the presence of albumin, higher concentrations of BCMA trispecific proteins were required to reduce the viability of EJM cells. Table 5 provides the EC values ​​for cell killing caused by BCMA trispecific proteins for EJM cells and Jeko, OPM2, MOL8, and NCI-H929 cells in the absence or presence of HSA. 50 For all five cell lines, the exemplary 02B05 BCMA trispecific antigen binding protein directed T cells to kill target cells in the presence of HSA.

[0430] Table 5: TDCC ECs of exemplary BCMA-targeting trispecific proteins in the presence or absence of human serum albumin using five different BCMA-expressing cell lines. 50 value

[0431]

[0432] Example 9

[0433] Exemplary BCMA-targeted trispecific protein mediates T cell activation using a low target cell to effector cell ratio Ability to kill BCMA-expressing cancer cells

[0434] In a standard TDCC assay (as described in Example 1), a ratio of 1 target cell (EJM cell or OPM2 cell) per 10 effector cells (T cells) was used in a 48-hour assay. In this experiment, the ability of the exemplary BCMA trispecific protein 02B05 (SEQ ID NO: 520) to direct T cells to kill target cells was tested at a lower target cell to effector cell ratio. It is expected that lower killing will be observed when fewer effector cells are used. Two BCMA-expressing cell lines, EJM and OPM2, were tested using a target cell to effector cell ratio of 1:1, 1:3, and 1:10, and the experiment was performed in the presence of 15 mg / ml HSA. A trispecific protein targeting GFP was used as a negative control. The data for this experiment are Figure 8 (TDCC assay using EJM cells) and Fig. 9 (TDCC assay using OPM2 cells). As expected, at a target cell to effector cell ratio of 1:10, almost complete killing of target cells was observed. As the effector cells were gradually reduced, the amount of killing decreased. The EC values ​​for cell killing at each ratio are listed in Table 6. 50 Values ​​(n / d) indicate that the observed killing was insufficient to calculate EC 50When fewer effector cells are present, EC 50 Thus, as expected, reducing the number of effector cells relative to target cells reduced the TDCC activity of the BCMA trispecific protein.

[0435] Table 6: TDCC ECs of an exemplary BCMA-targeting trispecific protein (02B05) using different ratios of target cells (EJM cells) to effector cells (T cells) (tested in the presence of 15 mg / ml HSA). 50 value

[0436]

[0437] Example 10

[0438] Using a lower target cell to effector cell ratio, an exemplary BCMA-targeted trispecific protein was expressed in a time course study. Protein mediates the ability of T cells to kill BCMA-expressing cancer cells

[0439] In the standard TDCC assay (Example 1), a ratio of 1 target cell per 10 effector cells (T cells) was used in a 48-hour assay. In this experiment, a time course was performed using a 1:1 ratio of target cells (EJM cells) to effector cells (T cells). It is expected that a 1:1 ratio will result in target cell killing over time. The experiment was performed in the presence of 15mg / ml HSA. A trispecific protein targeting GFP was used as a negative control. In the presence of an exemplary 02B05 BCMA trispecific antigen-binding protein and 15mg / ml HSA or GFP targeting trispecific protein and 15mg / ml HSA, after incubating target cells and effector cells at a ratio of 1:1, the viability of target cells was measured on days 1, 2, 3, and 4. Although target cell killing was not observed on day 1, killing was observed at all other time points in the presence of the BCMA trispecific antigen-binding protein, and the amount of killing increased over time ( Fig.10 ). No killing was observed with the trispecific protein targeting GFP. The EC calculated for cell killing per day are provided in Table 7. 50 Values ​​(n / d indicate insufficient killing to determine EC 50 From this study it was concluded that the exemplary 02B05 BCMA trispecific protein was able to direct T cell killing with a lower number of effector cells, but required more time to achieve more complete killing.

[0440] Table 7: TDCC ECs of an exemplary BCMA-targeting trispecific protein (02B05) at different time points using a 1:1 ratio of target cells (EJM cells) to effector cells (T cells) (tested in the presence of 15 mg / ml HSA). 50 value

[0441]

[0442]

[0443] Embodiment 11

[0444] Ability of exemplary BCMA-targeting trispecific proteins to direct human T cells to kill BCMA-expressing cells

[0445] Using the standard TDCC assay as described in Example 1, the exemplary BCMA trispecific protein 02B05 (SEQ ID NO: 520) was tested for its ability to guide T cells from four different anonymous human donors to kill four different BCMA-expressing cells in the presence of 15 mg / ml human serum albumin (HSA). The cell lines expressing BCMA are EJM, NCI-H929, OPM2, and RPMI8226. As negative controls, two cell lines lacking BCMA expression, OVCAR8 and NCI-H510A, were also tested in the TDCC assay. A control GFP targeting trispecific protein was also used as a negative control. For the four BCMA-expressing cell lines and all four T cell donors, cell viability decreased with increasing BCMA trispecific protein content, while GFP trispecific protein was not ( Fig.11 , 12 , 13 and 14). Table 8 provides the EC of cell killing 50 Exemplary 02B05 BCMA trispecific antigen binding protein does not induce killing of cell lines lacking BCMA expression ( Fig.15 and 16 ). Therefore, it was concluded that the exemplary 02B05 BCMA trispecific antigen binding protein was able to direct T cells from multiple donors to kill a range of BCMA-expressing cell lines.

[0446] Table 8: Exemplary 02B05 BCMA trispecific protein EC from TDCC assay using four BCMA expressing cell lines and four T cell donors in the presence of 15 mg / ml HSA 50 value

[0447]

[0448]

[0449] Example 12

[0450] Exemplary BCMA-targeting trispecific protein directs T cell killing expression in cynomolgus monkeys

[0451] BCMA cell capacity

[0452] The ability of the exemplary BCMA-targeting trispecific protein 02B05 (SEQ ID NO: 520) to direct T cells from cynomolgus monkeys to kill BCMA-expressing cells was tested in the presence of 15 mg / ml human serum albumin (HSA). The experimental conditions were the same as described in Example 1, except that peripheral blood mononuclear cells (PBMCs) from cynomolgus monkeys were used as the source of T cells. Two BCMA-expressing cell lines, RPMI8226 and NCI-H929, were tested. Fig.17 and 18 As shown, the BCMA trispecific protein was able to direct T cells present in cynomolgus monkey PBMC to kill these two BCMA-expressing cell lines. The ECs for cell killing are listed in Table 9. 50 The GFP trispecific protein did not affect the viability of cells expressing BCMA. Therefore, the trispecific protein expressing BCMA that can bind to cynomolgus monkey CD3ε (as shown in Example 5) can guide cynomolgus monkey T cells to kill cells expressing human BCMA.

[0453] Table 9: BCMA trispecific protein EC from TDCC assay using two cell lines and two cynomolgus PMBC donors in the presence of 15 mg / ml HSA 50 value

[0454]

[0455] Example 13

[0456] Exemplary BCMA trispecific antigen binding proteins and target tumor cell-mediated T cell activation induction

[0457] The ability of the exemplary BCMA-targeting trispecific protein 02B05 (SEQ ID NO: 520) to activate T cells in the presence of cells expressing BCMA was tested. The cell lines expressing BCMA are EJM, OPM2, and RPMI8226. As negative controls, two cell lines lacking BCMA expression, OVCAR8 and NCI-H510A, were also included. T cells were obtained from four different anonymous human donors. The assay was established using the conditions of the standard TDCC assay as described in Example 1, except that the assay was adapted for a 96-well format and the assay was performed in the presence of 15 mg / ml HSA. After 48 hours of assay, T cell activation was assessed by measuring the expression of T cell activation biomarkers CD25 and CD69 on the surface of T cells using flow cytometry. As the concentration of the exemplary 02B05 BCMA trispecific antigen binding protein increased, increased expression of CD69 and CD25 was observed on T cells when co-cultured with cells expressing BCMA (e.g., Figure 19-24Thus, the observed enhanced expression was dependent on the interaction of the BCMA binding sequence within the exemplary 02B05 BCMA trispecific antigen binding protein with BCMA, as the control GFP trispecific protein (as shown) Figure 19-24 ) or using target cells without BCMA expression (as shown Figure 25-28 Minimal or no activation was observed (as shown). Thus, the exemplary 02B05 BCMA trispecific antigen binding protein activated T cells in co-cultures containing cells expressing BCMA. This conclusion is supported by other data. For example, expression of the cytokine TNFα was measured in culture medium collected from co-cultures of T cells and target cells expressing BCMA, the target cells being treated with increasing concentrations of the exemplary 02B05 BCMA trispecific antigen binding protein or with a negative control GFP trispecific protein. Co-cultures were established using the conditions of a standard TDCC assay (as described in Example 1) supplemented with 15 mg / ml HSA. TNFα was measured using an electrochemiluminescence assay (Meso Scale Discovery). Robust induction of TNFα expression was observed using the 02B05 exemplary BCMA-targeted trispecific protein, while no induction was observed with the GFP trispecific protein ( Fig.29 ). This result further supports that the 02B05 exemplary BCMA-targeting trispecific protein activates T cells in co-cultures containing BCMA-expressing cells.

[0458] Embodiment 14

[0459] Pharmacokinetics of Exemplary BCMA-Targeting Trispecific Proteins of the Disclosure

[0460] A single intravenous dose of an exemplary BCMA-targeted trispecific protein (02B05) (SEQ ID NO: 520) was administered to cynomolgus monkeys at 0.01 mg / kg, 0.1 mg / kg, or 1 mg / kg. Each dose group included two animals. After administration, serum samples were collected and analyzed by two different electrochemiluminescent assays. One assay used biotinylated CD3ε as a capture reagent and sulfo-labeled BCMA for detection (referred to as a functional assay). Another assay used a biotinylated antibody as a capture reagent that recognizes the anti-albumin domain in the exemplary BCMA-targeted trispecific protein and a sulfo-labeled antibody as a detection reagent that recognizes the anti-CD3 binding domain (i.e., anti-idiotypic antibody) in the exemplary BCMA-targeted trispecific protein. The results of the electrochemiluminescent assay are plotted on Fig.32 In. Fig.32As shown, the exemplary BCMA-targeting trispecific protein was detected in cynomolgus monkey serum samples even after 504 hours after administration. Fig.32 The line marked with the term “functional” in the Fig.32 An exemplary BCMA-targeting trispecific protein is identified in FIG. 1 (line labeled with the term “anti-idiotype” in FIG. 1 ).

[0461] To confirm that the exemplary BCMA-targeting trispecific protein retained the ability to direct T cells to kill BCMA-expressing EJM cells after in vivo administration, serum samples from the 168 hour time point were tested in the TDCC assay (as described in Example 1) in the presence of 16.7% serum from cynomolgus monkeys that had not been exposed to the BCMA-targeting trispecific protein, and the exemplary BCMA-targeting trispecific protein ( Fig.33 Freshly diluted exemplary 02B05 BCMA trispecific proteins were compared to BCMA trispecific proteins collected from test cynomolgus monkeys at 168h. GFP trispecific proteins were included as negative controls. This study demonstrated that the exemplary BCMA-targeted trispecific proteins collected from test cynomolgus monkey serum had the same activity as freshly diluted proteins, and that the proteins in this serum sample retained the ability to direct T cells to kill target cells expressing BCMA.

[0462] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Those skilled in the art will now appreciate many variations, changes, and substitutions without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be employed in the process of implementing the present invention. It is intended that the scope of the present invention be defined by the following claims, and that methods and structures and their equivalents within the scope of these claims are thereby encompassed.

[0463] Sequence Listing

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494]

[0495]

[0496]

[0497]

[0498]

[0499]

[0500]

[0501]

[0502]

[0503]

[0504]

[0505]

[0506]

[0507]

[0508]

[0509]

[0510]

[0511]

[0512]

[0513]

[0514]

[0515]

[0516]

[0517]

[0518]

[0519]

[0520]

[0521]

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

Claims

1. A B cell maturation agent (BCMA) binding trispecific protein comprising: (a) a first domain (A) that specifically binds to human CD3, which is a single-chain variable fragment (scFv); (b) a second domain (B) that specifically binds to human serum albumin, which is a single domain antibody; and (c) a third domain (C) that specifically binds to human BCMA, which is a single domain antibody, wherein the third domain comprises complementarity determining regions CDR1, CDR2 and CDR3, and wherein the CDR1 comprises the amino acid sequence of SEQ ID NO:76, the CDR2 comprises the amino acid sequence of SEQ ID NO:190, and the CDR3 comprises the amino acid sequence of SEQ ID NO:

304.

2. The BCMA-binding protein of claim 1, wherein the first domain, the second domain, and the third domain are independently humanized.

3. The BCMA-binding trispecific protein of claim 1, wherein the third domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:

383.

4. The BCMA-binding trispecific protein of claim 3, wherein the third domain comprises the amino acid sequence of SEQ ID NO:

383.

5. The BCMA-binding trispecific protein of claim 1, wherein the first domain comprises heavy chain complementary determining regions HC CDR1, HC CDR2, and HC CDR3 and light chain complementary determining regions LC CDR1, LC CDR2, and LC CDR3; wherein the HC CDR1 comprises the amino acid sequence of GFTFNKYAIN (amino acid residues 278-287 of SEQ ID NO: 520), the HC CDR2 comprises the amino acid sequence of RIRSKYNNYATYYADQVK (amino acid residues 302-319 of SEQ ID NO: 520), and the HC CDR3 comprises the amino acid sequence of HANFGNSYISYWAY (amino acid residues 353-366 of SEQ ID NO: 520); and wherein the LC CDR1 comprises the amino acid sequence of ASSTGAVTSGNYPN (amino acid residues 415-428 of SEQ ID NO: 520), the LC CDR2 comprises the amino acid sequence of GTKFLVP (amino acid residues 444-450 of SEQ ID NO: 520), and the LC CDR3 comprises the amino acid sequence of TLWYSNRWV (amino acid residues 483-491 of SEQ ID NO: 520).

6. The BCMA-binding trispecific protein of claim 5, wherein the first domain comprises an amino acid sequence having at least 90% sequence identity to the following sequence: EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVL (amino acid residues 253-501 of SEQ ID NO: 520).

7. The BCMA-binding trispecific protein of claim 6, wherein the first domain comprises the following amino acid sequence: EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGG GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVL(SEQID Amino acid residues 253-501 of NO:520).

8. The BCMA-binding trispecific protein of claim 1, wherein the second domain (B) comprises complementarity determining regions CDR1, CDR2, and CDR3, and wherein the CDR1 comprises the amino acid sequence of GFTFSKFGMS (amino acid residues 154-163 of SEQ ID NO: 520), the CDR2 comprises the amino acid sequence of SISGSGRDTLYADSVK (amino acid residues 178-193 of SEQ ID NO: 520), and the CDR3 comprises the amino acid sequence of GGSLSV (amino acid residues 227-232 of SEQ ID NO: 520).

9. The BCMA-binding trispecific protein of claim 8, wherein the second domain (B) comprises an amino acid sequence having at least 90% sequence identity to the following sequence: EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLE WVSSISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSS (amino acid residues 129-243 of SEQ ID NO: 520).

10. The BCMA-binding trispecific protein of claim 9, wherein the second domain (B) comprises the following amino acid sequence: EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLE WVSSISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAV YYCTIGGSLSVSSQGTLVTVSS (amino acid residues 129-243 of SEQ ID NO: 520).

11. The BCMA-binding trispecific protein of claim 1 , wherein the linker sequence of the domains is H2N-(C)-(B)-(A)-COOH.

12. The BCMA-binding trispecific protein of claim 11, wherein the domains are linked by at least one linker.

13. The BCMA-binding trispecific protein of claim 1, wherein the BCMA-binding trispecific protein has an EC of no higher than 1.0E-11 M in vitro. 50 Induces T cell-dependent cytotoxicity (TDCC) of BCMA-positive cells.

14. A B cell maturation agent (BCMA) binding trispecific protein comprising: (a) the first domain (A) that specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) that specifically binds to BCMA, wherein the third domain comprises complementarity determining regions CDR1, CDR2 and CDR3, and wherein: (i) the CDR1 comprises the sequence of TNIFSTSPMG (SEQ ID NO: 49), The CDR2 comprises the sequence of AIHGFSTIYADSVK (SEQ ID NO: 163), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 277); (ii) the CDR1 comprises the sequence of TNIFSTSPYG (SEQ ID NO: 114), and the CDR2 comprises the sequence of AIHGFSTIYADSVK (SEQ ID NO: 228), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 342); (iii) the CDR1 comprises the sequence of TNIFSTSPGG (SEQ ID NO: 115), The CDR2 comprises the sequence of AIHGFSTIYADSVK (SEQ ID NO: 229), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 343); (iv) the CDR1 comprises the sequence of TNIQSISPMG (SEQ ID NO: 57), The CDR2 comprises the sequence of AIHGFETLYADSVK (SEQ ID NO: 171), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 285); (v) the CDR1 comprises the sequence of TNIMSISPMG (SEQ ID NO: 65), The CDR2 comprises the sequence of AIHGFSTVYADSVK (SEQ ID NO: 179), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 293); (vi) the CDR1 comprises the sequence of TNIFSNSPMG (SEQ ID NO: 77), The CDR2 comprises the sequence of AIHGFSTLYADSVK (SEQ ID NO: 191), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 305); (vii) the CDR1 comprises the sequence of TNIFSRSPMG (SEQ ID NO: 89), The CDR2 comprises the sequence of AIHGISTLYADSVK (SEQ ID NO: 203), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 317); (viii) the CDR1 comprises the sequence of TNIFSDSPMG (SEQ ID NO: 90), The CDR2 comprises the sequence of AIHGFSTFYADSVK (SEQ ID NO: 204), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 318); (ix) the CDR1 comprises the sequence of TNIFSKSPMG (SEQ ID NO: 92), The CDR2 comprises the sequence of AIHGSSTLYADSVK (SEQ ID NO: 206), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 320); (x) the CDR1 comprises the sequence of TNIFSSSPMG (SEQ ID NO: 94), and the CDR2 comprises the sequence of AIHGFSTLYADSVK (SEQ ID NO: 208), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 322); (xi) the CDR1 comprises the sequence of TNIFSITPMG (SEQ ID NO: 101), and the CDR2 comprises the sequence of AIHGASTLYADSVK (SEQ ID NO: 215), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 329); (xii) the CDR1 comprises the sequence of TNIFSITPYG (SEQ ID NO: 116), and the CDR2 comprises the sequence of AIHGASTLYADSVK (SEQ ID NO: 230), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 344); or (xiii) the CDR1 comprises a sequence of TNIFSITPGG (SEQ ID NO: 117), and the CDR2 comprises a sequence of AIHGASTLYADSVK (SEQ ID NO: 231), and the CDR3 comprises the sequence of VPWGDYHPGNVY (SEQ ID NO: 345); The linking order of the domains is H2N-(C)-(B)-(A)-COOH.

15. The BCMA-binding trispecific protein of claim 14, wherein the BCMA-binding trispecific protein has an EC of no higher than 1.0E-11 M in vitro. 50 Induces T cell-dependent cytotoxicity (TDCC) of BCMA-positive cells.

16. A polynucleotide encoding the BCMA-binding tri-specific protein according to any one of claims 1 to 15.

17. A pharmaceutical composition comprising the BCMA-binding trispecific protein according to any one of claims 1 to 15 or the polynucleotide according to claim 16 and a pharmaceutically acceptable excipient.

18. Use of the BCMA-binding trispecific protein according to any one of claims 1 to 15 or the polynucleotide according to claim 16 in the preparation of a medicament for treating a cancer of the B-cell lineage.

19. The use according to claim 18, wherein the B-cell lineage cancer comprises multiple myeloma, leukemia, lymphoma or metastasis thereof.

20. A method for producing a BCMA-binding trispecific protein according to any one of claims 1 to 14, comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the BCMA-binding trispecific protein under conditions allowing expression of the BCMA-binding trispecific protein, and recovering and purifying the produced protein from the culture.

21. A B cell maturation agent (BCMA) binding trispecific protein comprising: (a) the first domain (A) that specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) the third domain (C) that specifically binds to BCMA, wherein the domains are linked in the order of H2N-(A)-(C)-(B)-COOH, H2N-(B)-(A)-(C)-COOH, H2N-(C)-(B)-(A)-COOH, H2N-(C)-(A)-(B)-COOH, H2N-(A)-(B)-COOH, or H2N-(B)-(C)-(A)-COOH, wherein the domains are linked by linkers L1 and L2; wherein the third domain comprises a VHH domain, the VHH domain comprises complementarity determining regions CDR1, CDR2 and CDR3, wherein the CDR1 comprises an amino acid sequence shown in any one of SEQ ID NOs: 4-117, the CDR2 comprises an amino acid sequence shown in any one of SEQ ID NOs: 118-231, and the CDR3 comprises an amino acid sequence shown in any one of SEQ ID NOs: 232-345.